<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id>
<journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id>
<journal-title-group>
<journal-title>The Journal of Headache and Pain</journal-title>
</journal-title-group>
<issn pub-type="ppub">1129-2369</issn>
<issn pub-type="epub">1129-2377</issn>
<publisher>
<publisher-name>Springer Milan</publisher-name>
<publisher-loc>Milan</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28194570</article-id>
<article-id pub-id-type="pmc">5307402</article-id>
<article-id pub-id-type="publisher-id">711</article-id>
<article-id pub-id-type="doi">10.1186/s10194-016-0711-0</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetic and biochemical changes of the serotonergic system in migraine pathobiology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gasparini</surname>
<given-names>Claudia Francesca</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smith</surname>
<given-names>Robert Anthony</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Griffiths</surname>
<given-names>Lyn Robyn</given-names>
</name>
<address>
<phone>+61 7 3138 6102</phone>
<email>lyn.griffiths@qut.edu.au</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0437 5432</institution-id><institution-id institution-id-type="GRID">grid.1022.1</institution-id><institution></institution><institution>Menzies Health Institute Queensland, Griffith University Gold Coast, </institution></institution-wrap>Parklands Drive, Southport, QLD 4222 Australia </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000089150953</institution-id><institution-id institution-id-type="GRID">grid.1024.7</institution-id><institution>Genomics Research Centre, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, </institution><institution>Queensland University of Technology, </institution></institution-wrap>Musk Ave, Kelvin Grove, QLD 4059 Australia </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>13</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>18</volume>
<issue>1</issue>
<elocation-id>20</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>12</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>Migraine is a brain disorder characterized by a piercing headache which affects one side of the head, located mainly at the temples and in the area around the eye. Migraine imparts substantial suffering to the family in addition to the sufferer, particularly as it affects three times more women than men and is most prevalent between the ages of 25 and 45, the years of child rearing. Migraine typically occurs in individuals with a genetic predisposition and is aggravated by specific environmental triggers. Attempts to study the biochemistry of migraine began as early as the 1960s and were primarily directed at serotonin metabolism after an increase of 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of serotonin was observed in urine of migraineurs. Genetic and biochemical studies have primarily focused on the neurotransmitter serotonin, considering receptor binding, transport and synthesis of serotonin and have investigated serotonergic mediators including enzymes, receptors as well as intermediary metabolites. These studies have been mainly assayed in blood, CSF and urine as the most accessible fluids. More recently PET imaging technology integrated with a metabolomics and a systems biology platform are being applied to study serotonergic biology. The general trend observed is that migraine patients have alterations of neurotransmitter metabolism detected in biological fluids with different biochemistry from controls, however the interpretation of the biological significance of these peripheral changes is unresolved. In this review we present the biology of the serotonergic system and metabolic routes for serotonin and discuss results of biochemical studies with regard to alterations in serotonin in brain, cerebrospinal fluid, saliva, platelets, plasma and urine of migraine patients.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Migraine with aura</kwd>
<kwd>Migraine without aura</kwd>
<kwd>Cortical spreading depression</kwd>
<kwd>Serotonin</kwd>
<kwd>Metabolomics</kwd>
<kwd>Melatonin</kwd>
<kwd>Tryptophan</kwd>
<kwd>Triptans</kwd>
<kwd>SERT</kwd>
<kwd>Kyneurine pathway</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec200">
<title>Review</title>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p>Migraine is a painful neurological disease whose manifestation results from an interplay of enviro-genomic factors and the severity of symptoms often propels sufferers to abuse medication. Migraine reigns as the 8<sup>th</sup> most burdensome disease in the world and the 4<sup>th</sup> most in women according to the 2012 Global Burden of Disease study [<xref ref-type="bibr" rid="CR1">1</xref>]. The clinical features of migraine according to IHS classification include intense, pulsating head pain localized to one side of the head that can effectively disable its sufferer for up to 72 h [<xref ref-type="bibr" rid="CR2">2</xref>]. Accompanying symptoms of migraine in addition to the headache include nausea, vomiting, and hypersensitivity to lights, sounds and/or smells, all of which can be aggravated by physical activity [<xref ref-type="bibr" rid="CR2">2</xref>]. The disease is believed to develop in genetically vulnerable populations, disabling an estimated 12% of Caucasian people, varying in accordance with genetic background, climatic region, socioeconomic status, life-style, presence of other diseases and the general health of the sourced population [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. There is also a well-established overrepresentation of the disease in females, affecting ~3 times more females than males due to a complex interplay of hormonal and enviro-genomic exposures [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p>Migraine is diagnosed by specialized physicians utilizing the current International Headache Society (IHS) criteria (ICHD-3, beta version currently available at <ext-link ext-link-type="uri" xlink:href="https://www.ichd-3.org/">https://www.ichd-3.org/</ext-link>) [<xref ref-type="bibr" rid="CR2">2</xref>]. Acceptance of these criteria has facilitated modern day molecular genetic research by standardising diagnosis of headache and headache-related disorders in absence of any clearly identifiable pathology, biomarkers and diagnostic tests. Migraine is classified into two main types, distinguished by the presence of a variety of sensory disturbances (termed aura) that can occur in the early stages of the headache: migraine with aura (MA) or migraine without aura (MO) [<xref ref-type="bibr" rid="CR2">2</xref>]. Migraine is a complex disorder that evolves due to a combination of multiple genes and external factors such as gene-environment, gene-nutrient, gene-gene interactions and epigenetics that result in multiple presentations of the disorder making it difficult to pinpoint the relevant genomic risk factors [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
<p>Literature on the pathophysiology of migraine continues to evoke a disorder of neurovascular origin as demonstrated by the involvement of cranial neurovascular anatomical structures. This neurovascular scaffold encompasses three main domains: a neural domain (i.e., hyperexcitability and CSD-like neural events) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], vascular domain (intracranial constriction and vasodilation) and a nociceptive domain (activation of trigeminal structures, a network of neurons that sense pain signals and release of several ‘migraine mediators’, neuropeptides, such as CGRP). These three domains describe the main aspects of the current model of the pathobiology of migraine [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. Genetic studies have focused on investigating genetic variability in multiple neurotransmitter systems which interact and overlap at different levels.</p>
<p>Neurotransmitters regulate intracellular signal transduction events as well as neural function, morphology and circuit formation [<xref ref-type="bibr" rid="CR12">12</xref>]. Interruptions in intra- and interneuronal signalling due to inappropriate activation or inactivation of regulatory proteins, including nuclear transcription factors can alter the electrophysiological signalling of neurons resulting in structural and functional changes [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref>]. This hypothesis of ‘malfunctioning ion channels’ that set the electrical activity in nerve cells that form circuits modulating pain was revived by the discovery of mutations in the potassium channel TRESK [<xref ref-type="bibr" rid="CR15">15</xref>]. Similarly, the recognition that the three main types of Familial Hemiplegic Migraine are caused by mutations in ion channels implies that ion channel dysfunction may be the primary cause for migraine symptoms in non-familial cases as well [<xref ref-type="bibr" rid="CR16">16</xref>]. In this review we considered the biology of the serotonergic system and its metabolism and results of biochemical studies regarding the content of serotonin in the brain, cerebrospinal fluid (CSF), saliva, platelets, plasma and urine of migraine patients and we link the evidence together in a biochemical model that considers the application of metabolomics for guiding future research on the pathobiology of migraine.</p>
</sec>
<sec id="Sec2">
<title>Serotonergic biology and genetics</title>
<p>Biochemical, genetic and pharmacological studies have investigated potential dysfunction of neurotransmitters in migraine susceptibility. The involvement of serotonin in migraine has been known for many years following Sicuteri’s observations of an increase of 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of serotonin, in the urine of 15 patients during migraine attacks [<xref ref-type="bibr" rid="CR17">17</xref>]. This was the first indication of an anomaly of serotonin metabolism in migraineurs and since then, many scientific research studies have focused on the genetic components of the serotonergic system (see Table <xref ref-type="table" rid="Tab1">1</xref>). Receptors, transporters and enzymes are the key molecular mediators that regulate and maintain serotonin levels in the brain and periphery. Serotonin is distributed in neuronal and several non-neuronal tissues of the cardiovascular system, gastrointestinal, renal systems and the blood [<xref ref-type="bibr" rid="CR18">18</xref>]. Serotonin regulates a wide array of physiological functions via a specific set of receptors which are mostly G protein-coupled receptors (except receptor 5HT3 which is a ligand gated cation channel) that activate an intracellular second messenger cascade to mediate excitatory or inhibitory neurotransmission [<xref ref-type="bibr" rid="CR19">19</xref>]. Serotonin receptors have been localized in vestibular and trigeminal ganglion cells in monkey [<xref ref-type="bibr" rid="CR20">20</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Genetic components of the serotonergic system</p></caption><table frame="hsides" rules="groups"><tbody><tr valign="top"><td>Enzyme</td><td>Gene</td><td>Locus</td><td>Function</td><td>Significance for migraine</td></tr><tr valign="top"><td>Tryptophan hydroxylase 1</td><td>TPH1</td><td>11p15.3-p14</td><td>TPH1, peripheral form, converts tryptophan to 5 hydroxy tryptophan, rate-limiting step in the synthesis of 5-HT, determines the availability of 5-HT and its rate of production.</td><td>TPH enzymes regulate brain-specific serotonin deficiency, weak association [<xref ref-type="bibr" rid="CR43">43</xref>].</td></tr><tr valign="top"><td>Tryptophan hydroxylase 2</td><td>TPH2</td><td>12q21.1</td><td>TPH2, neuronal form, synthesis of serotonin.</td><td></td></tr><tr valign="top"><td>Monoamine oxidase A</td><td>MAO-A</td><td>Xp11.3</td><td>MAO-A, outer mitochondrial membrane, oxidative deamination of amines, such as dopamine, norepinephrine, and serotonin.</td><td>Enzymes metabolise triptans.</td></tr><tr valign="top"><td>Monoamine oxidase B</td><td>MAO-B</td><td>Xp11.23</td><td>MAO-B, both subtypes have a widespread occurrence in the brain and in peripheral tissues.</td><td>MAO inhibitors promote the accumulation of monoamines and reduce uncontrolled vasodilation, and were used in treating migraine but discontinued<break></break>due to side effects [<xref ref-type="bibr" rid="CR73">73</xref>].</td></tr><tr valign="top"><td>Amino acid decarboxylase</td><td>DDC</td><td>7p12.2</td><td>DDC, catalyses the decarboxylation of L-5-hydroxytryptophan to 5-HT and L-tryptophan to tryptamine.</td><td>Gene variations have been investigated in relation to neuropsychiatric disorders.</td></tr><tr valign="top"><td>Aldehyde dehydrogenase 2</td><td>ALDH2</td><td>12q24.2</td><td>ALDH2, located in mitochondria produce 5-hydroxyindole acetic acid as the major excreted metabolite of serotonin.</td><td></td></tr><tr valign="top"><td>Receptor Protein</td><td>Gene</td><td>Locus</td><td>Potential and mechanism</td><td>Significance for migraine</td></tr><tr valign="top"><td rowspan="5">5HT1</td><td>HTR1A</td><td>5q11.2-q13</td><td>Inhibitory, decreasing cellular levels of cAMP</td><td></td></tr><tr valign="top"><td>HTR1B</td><td>6q13</td><td></td><td>Co-localization of 5HT1<sub>B</sub>, 5HT1<sub>D</sub> and HTR1<sub>F</sub> receptor subtypes in vestibular ganglia [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].<break></break>Triptans have high affinity for serotonin receptors.</td></tr><tr valign="top"><td>HTR1D</td><td>1p36.3-p34.3</td><td></td><td></td></tr><tr valign="top"><td>HTR1E</td><td>6q14-q15</td><td></td><td></td></tr><tr valign="top"><td>HTR1F</td><td>3p12</td><td></td><td>Lasmiditan is a 5-HT1F receptor agonist by non-vascular mechanism [<xref ref-type="bibr" rid="CR75">75</xref>].</td></tr><tr valign="top"><td rowspan="3">5HT2</td><td>HTR2A</td><td>13q14-q21</td><td>Excitatory, increasing cellular levels of IP3 and DAG</td><td>Cortical density of the excitatory 5-HT2 receptor, which is involved in pain processing, is not altered interictally in migraine patients [<xref ref-type="bibr" rid="CR76">76</xref>].</td></tr><tr valign="top"><td>HTR2B</td><td>2q36.3-q37.1</td><td></td><td></td></tr><tr valign="top"><td>HTR2C</td><td>Xq24</td><td></td><td>Positive association in SNP in HTR2C promoter in Turkish population with migraine [<xref ref-type="bibr" rid="CR40">40</xref>].</td></tr><tr valign="top"><td rowspan="5">5HT3</td><td>HTR3A</td><td>11q23.1</td><td>Excitatory, depolarizing plasma membrane</td><td>Role in facilitation of inflammatory and neuropathic pain [<xref ref-type="bibr" rid="CR77">77</xref>].</td></tr><tr valign="top"><td>HTR3B</td><td>11q23.1</td><td></td><td></td></tr><tr valign="top"><td>HTR3C</td><td>3q27.1</td><td></td><td></td></tr><tr valign="top"><td>HTR3D</td><td>3q27.1</td><td></td><td></td></tr><tr valign="top"><td>HTR3E</td><td>3q27.1</td><td></td><td></td></tr><tr valign="top"><td>5HT4</td><td>HTR4A</td><td>5q31-q33</td><td>Excitatory, increasing cellular levels of cAMP</td><td>Central 5-HT4 receptor binding might serve as a biomarker of serotonergic tonus in the human brain [<xref ref-type="bibr" rid="CR78">78</xref>].</td></tr><tr valign="top"><td rowspan="2">5HT5</td><td>HTR5A</td><td>7q36.1</td><td>Inhibitory, Decreasing cellular levels of cAMP</td><td></td></tr><tr valign="top"><td>HTR5B</td><td>2q14.1</td><td></td><td></td></tr><tr valign="top"><td>5HT6</td><td>HTR6A</td><td>1p36-p35</td><td>Excitatory, increasing cellular levels of cAMP</td><td></td></tr><tr valign="top"><td>5HT7</td><td>HTR7A</td><td>10q21-q24</td><td>Excitatory, increasing cellular levels of cAMP</td><td>5-HT7 receptor activation promotes NMDA-evoked currents [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. 5-HT7 receptor has differing roles in peripheral versus central pain mediation and is clinically relevant for the treatment of depression, a migraine co-morbidity [<xref ref-type="bibr" rid="CR81">81</xref>].</td></tr><tr valign="top"><td>Transporter protein</td><td>Gene</td><td>Locus</td><td>Function</td><td>Significance for migraine</td></tr><tr valign="top"><td>Serotonin transporter, SERT</td><td>SLC6A4</td><td>17q11.2</td><td>Reuptakes serotonin from the synapse, role in psychiatric disease</td><td>Meta-analyses by the groups of Liu and Schurks report a positive association with SERT and migraine [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</td></tr><tr valign="top"><td>Plasma membrane monoamine transporter, PMAT</td><td>SLC629A4</td><td>7p22.1</td><td>Transport of both serotonin and dopamine</td><td></td></tr></tbody></table><table-wrap-foot><p>
<italic>5-HT</italic> 5-hydroxytryptamine, <italic>cAMP</italic> cyclic adenosine monophosphate, <italic>IP3</italic> inositol trisphosphate, <italic>DAG</italic> diacylglycerol, <italic>SNP</italic> single nucleotide polymorphism</p><p>Note: PMAT (Plasma membrane monoamine transporter) is involved in the transport of both serotonin and dopamine</p></table-wrap-foot></table-wrap>
</p>
<p>Current research on the biology of the serotonergic system in disease is focusing on genetic alterations in synaptic and post-receptor signalling proteins that affect serotonergic neurotransmission by increasing or decreasing serotonin’s actual or effective availability in the CNS (See Table <xref ref-type="table" rid="Tab1">1</xref>) [<xref ref-type="bibr" rid="CR21">21</xref>]. Genetic variability at the level of gene transcription, mRNA processing and translation or post-translational modification as well as intracellular trafficking in the genetic components of the serotonergic system may generate gene products that may lead to structural and functional changes in brain circuits and provoke disease [<xref ref-type="bibr" rid="CR22">22</xref>]. The two most studied components of the serotonergic system that have come into the spotlight in determining susceptibility to migraine as well as multiple neuropsychiatric disorders are the serotonin transporter (SERT, also known as SLC6A4), which reuptakes serotonin from the synapse, and monoamine oxidase A (MAOA), an important enzyme that degrades serotonin and metabolizes triptans [<xref ref-type="bibr" rid="CR23">23</xref>]. Both these proteins are important in regulating levels of serotonin in the brain and carry polymorphisms in their promoter regions that cause differential transcriptional activity and thus impact drug metabolism [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR26">26</xref>].</p>
<p>Several association studies have investigated genetic variants that may alter the functions of genes involved in serotonin functionality and regulation. The serotonin transporter gene <italic>SERT</italic> has been extensively studied. In this gene, two polymorphisms have been of particular interest. The first polymorphism consists of a 17 bp variable number of tandem repeats known as (STin2 VNTR) in intron 2 with two common alleles (STin2.10 and STin2.12) composed of 10 or 12 repeat units respectively [<xref ref-type="bibr" rid="CR27">27</xref>]. To get a clearer picture, Schurks et al., [<xref ref-type="bibr" rid="CR27">27</xref>] considered five studies that evaluated the 5-HTT VNTR STin2 polymorphism and concluded the STin2 12/12 genotype may be influential in determining migraine susceptibility among populations of European descent. A further meta-analysis by Liu et al., [<xref ref-type="bibr" rid="CR28">28</xref>] reviewed 15 studies and found that the 5-HTT VNTR STin2 12/12 genotype confers an increased risk for migraine in the general population.</p>
<p>The second polymorphism is a 44-bp insertion/deletion functional polymorphism in the promoter region known as 5-HTTLPR. There are two common allelic forms, and the 14 repeat containing short variant (S) is associated with slower clearing of serotonin from the synaptic cleft [<xref ref-type="bibr" rid="CR29">29</xref>]. Analysis of this polymorphism has provided conflicting results. The S allele has shown association with migraine in some studies [<xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR33">33</xref>] while in other studies no evidence of association was identified [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. In a meta-analysis of 10 studies of Europeans and Asians Schurks et al., reported no overall association between the 5-HTTLPR polymorphism and migraine, although gender and migraine aura status may influence results among Europeans [<xref ref-type="bibr" rid="CR29">29</xref>]. Although various polymorphisms in serotonin related genes have showed altered allelic distribution in different migraine populations there has been, to date, insufficient evidence to confirm a specific serotonin receptor gene being directly associated with the disorder [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p>
<p>Genetic studies continue to provide new data regarding the involvement of serotonin in migraine and in particular support the idea that migraine is a polygenic disorder as recently reported in a large meta-analysis of 375,000 individuals by Gormley et al., [<xref ref-type="bibr" rid="CR38">38</xref>] that identified 38 susceptibility loci for migraine. Thompson et al. identified a positive association at the <italic>5-HT1D</italic> receptor locus in 64 extended families with migraine with aura [<xref ref-type="bibr" rid="CR39">39</xref>]. The locus 1p36 for the <italic>5-HT1D</italic> gene is a candidate locus because it is a target of triptan drugs and it was also considered in the context of the association of PRDM16 in MO which is located proximally to 1p36. Recently, a significant association was identified between migraine and a functional polymorphism rs3813929 localised in the promoter region of the serotonin receptor gene 5-HT2C [<xref ref-type="bibr" rid="CR40">40</xref>]. The T allele of this polymorphism affects the transcription rate of the 5-HT2C receptor and was more common in a Turkish population with migraine [<xref ref-type="bibr" rid="CR41">41</xref>].</p>
<p>Additionally, genetic research has explored serotonin synthesis and its role in migraine. Serotonin is synthesized in a short metabolic pathway consisting of two enzymes: tryptophan hydroxylase (TPH) and amino acid decarboxylase (DDC) (See Table <xref ref-type="table" rid="Tab1">1</xref>) [<xref ref-type="bibr" rid="CR42">42</xref>]. The TPH2 gene is an obvious candidate to genotype because in theory low activity of this enzyme may decrease the amount of serotonin available in the brain. However, a study by Jung et al., [<xref ref-type="bibr" rid="CR43">43</xref>], did not find a positive association with migraine for two SNPs (rs1487275 and rs1386486) in the TPH2 gene (TPH1 is the peripheral form, TPH2 is the neuronal form) in a population of 503 migraineurs and 515 healthy controls [<xref ref-type="bibr" rid="CR43">43</xref>]. Although this study does not support TPH2 as a key player in the migraine circuit TPH2 is emerging as a therapeutic target for stress disorders and abnormalities in TPH activity have been implicated in a variety of psychiatric disorders [<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR46">46</xref>]. Conceivably, there may be other effects, including epigenetic, gene regulatory and or expression effects affecting this locus yet to be determined [<xref ref-type="bibr" rid="CR44">44</xref>]. These data together with TPH2 knockout mice have provided additional insights into the role of TPH enzymes in regulating brain-specific serotonin deficiency [<xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR49">49</xref>].</p>
<sec id="Sec3">
<title>Migraine therapy and triptans</title>
<p>Triptans are currently the most effective drugs in treating migraine and are the supporting pillar of migraine therapy [<xref ref-type="bibr" rid="CR50">50</xref>]. Triptans amplify the serotonin signal by stimulating serotonin receptors located in cranial blood vessels and nerve endings and relieve pain by constricting blood vessels and inhibiting the release of peptides, including CGRP [<xref ref-type="bibr" rid="CR51">51</xref>] and substance P as well as acting in other ways not yet known [<xref ref-type="bibr" rid="CR52">52</xref>]. At the cellular level triptans alleviate migraine symptoms by binding to serotonin 5-HT1b, d and f receptors along pain signaling circuits and are effective due to high receptor specificity and disease specificity [<xref ref-type="bibr" rid="CR53">53</xref>]. Recent studies [<xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR56">56</xref>] continue to reveal triptans complex actions including meta-analyses comparing the effectiveness of triptans alone or in combination with other drugs [<xref ref-type="bibr" rid="CR57">57</xref>]. Although triptans are the most effective drugs for migraine they exhibit therapeutic variability in different patient groups. The different levels of drug response can be explained by different metabolic routes, rates and efficiency.</p>
<p>In a meta-analysis by Cameron et al., 133 randomized controlled trials were included and the conclusion from this study was that triptans are generally better than ergots and provide equal or better pain relief when compared with non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid (ASA) and acetaminophen [<xref ref-type="bibr" rid="CR57">57</xref>]. Triptans used in combination with ASA or acetaminophen, or by alternative administration methods (injectables) yielded slightly better outcomes than standard dose triptan tablets. Thorlund et al., evaluated the efficacy of seven triptans in a multiple treatment comparison meta-analysis by examining data from 74 double-blinded randomized clinical trials comparing triptans to either placebo or to another triptan [<xref ref-type="bibr" rid="CR58">58</xref>]. Among the seven different triptans tested, eletriptan was the best triptan and all triptans were found better than placebo [<xref ref-type="bibr" rid="CR58">58</xref>]. This result was also upheld by a recent report showing that triptans still have the most favorable efficacy-tolerability profile [<xref ref-type="bibr" rid="CR59">59</xref>].</p>
<p>The hunt for better more specific drugs continues particularly in the era of pharmacogenetic research whose goal is to evaluate the impact of genetic constitution on migraine drug response [<xref ref-type="bibr" rid="CR60">60</xref>]. Pharmacogenetics recognizes that numerous genes (drug metabolizing enzymes and drug transporters) play a role in the mechanism of drug response, resistance, toxicity, drug transport or drug targeting and ultimately affect how patients metabolize and consequently respond to different drug regimens [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. This information can help inform doctors prescribing practices ie. responders versus non-responders, avoiding adverse drug reactions, optimizing drug dose for the individual and ultimately guide prescription of the ‘right’ triptan to the ‘right’ patient [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
<p>In a study by Terazzino et al., the STin2 VNTR polymorphism in the SERT gene was shown to be associated with a higher risk of inconsistent response to triptans in migraine patients [<xref ref-type="bibr" rid="CR64">64</xref>]. However the authors caution some limitations in their study such as a small sample size but nevertheless support future pharmacogenetic testing to identify algorithms for more effective treatment [<xref ref-type="bibr" rid="CR64">64</xref>]. Recently, Christensen et al. identified a single risk variant, rs2651899 in the PRDM16 gene among 12 single nucleotide polymorphisms (SNPs) genotyped chosen based on prior GWAS findings by Antilla [<xref ref-type="bibr" rid="CR65">65</xref>] to be significantly associated with efficacy of triptans [<xref ref-type="bibr" rid="CR60">60</xref>]. To explore the role of genetic factors in drug metabolism Gentile et al., 2010 genotyped polymorphisms in CYP450 and MAOA, genes that are involved in Phase I metabolic reactions, and in target mechanisms (GNB3) of triptans and reported a significant correlation between MAOA uVNTR polymorphism and a chronic migrainous population [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Serotonin receptors are also targeted by other drugs besides triptans and in a study by Brandl et al., polymorphisms in serotonergic genes (HTR2A, SERT) were found to be associated with antipsychotic treatment response [<xref ref-type="bibr" rid="CR68">68</xref>].</p>
<p>In addition to pharmacogenomics a new paradigm has emerged ‘pharmacometabolomics’ for characterizing the metabolic (pharmacokinetic and pharmacodynamic) response to a drug taking into account both environmental and genomic factors [<xref ref-type="bibr" rid="CR69">69</xref>]. Although there is still a paucity of studies in this domain, recent studies are using both metabolomic and genomic data to study selective serotonin reuptake inhibitor (SSRI) treatment outcomes in patients with major depressive disorder (MDD) by use of a “pharmacometabolomic-informed” pharmacogenomic research strategy [<xref ref-type="bibr" rid="CR70">70</xref>]. In a follow up study in 2016, Gupta et al., uncovered two main SNP signals in two candidate genes (TSPAN5 and ERICH3) which were associated with the clinical response to SSRI therapy in MDD patients [<xref ref-type="bibr" rid="CR71">71</xref>]. Functional genomic studies assessed serotonin pathway enzyme expression after knockdown (KD) or over-expression (OE) of TSPAN5 and ERICH3 in neurally-derived cell lines by qRT-PCR and quantitative Western blot. KD of TSPAN5 was associated with a significant decrease of mRNA and protein levels for the serotonin pathway enzymes TPH1, TPH2, DDC, MAOA, as well as the serotonin transporter SLC6A4. Both TSPAN5 and ERICH3 proteins affect serotonin concentrations in cell culture media. The identification of ERICH3 and TSPAN5 in the regulation of serotonin or variation in SSRI response is novel and recent studies have reported TSPAN5 may also promote Notch signalling [<xref ref-type="bibr" rid="CR72">72</xref>].</p>
<p>Although specific SNPs in genes that metabolize triptans have yet to be identified, current pharmacogenetics studies indicate that defining the effect SNPs have on drug metabolism and treatment response may have value in classifying patients into groups of poor metabolizers to predict therapeutic responses and to evaluate sex differences. Several studies have shown that SNPs in genes of most metabolic enzymes can affect enzyme activities and may account for inter-individual variation, in drug bioavailability and efficacy and consequently can bear a role in therapy response [<xref ref-type="bibr" rid="CR63">63</xref>]. Results of future testing the clinical utility of SNPs and genetic variability in the signalling components of the serotonergic system as well as additional genes involved in triptan metabolism will impact patient care and may be useful to personalize medicine.</p>
</sec>
<sec id="Sec4">
<title>Metabolic routes of serotonin</title>
<sec id="FPar100">
<title>Tryptophan - Indole-kynurenine-niacin pathway</title>
<p>Tryptophan is a requisite precursor necessary for various metabolic reactions primarily the synthesis of serotonin, proteins, melatonin, tryptamine and kynuramines [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. In the body, tryptophan is metabolized, via two basic pathways, the indole-kynurenine-niacin pathway and the serotonin-melatonin pathway [<xref ref-type="bibr" rid="CR84">84</xref>]. The majority of tryptophan, 99% is metabolized and degraded along the kynurenine pathway which generates neuroactive compounds collectively called the kynurenines that antagonize the NMDA receptors [<xref ref-type="bibr" rid="CR85">85</xref>]. Several studies of neurological diseases have reported kynurenine pathway (KP) metabolites and/or enzyme activity to be up- and/or down-regulated in relation to disease [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. Recently Curto et al., identified an association of fluctuations of kynurenine metabolites in serum samples from 21 cluster headache patients [<xref ref-type="bibr" rid="CR88">88</xref>]. Curto et al., also identified altered kynurenine pathway metabolites in serum of chronic migraine patients [<xref ref-type="bibr" rid="CR89">89</xref>]. Indeed activation or inhibition of kynurenine pathway enzymes and accumulation of kynurenines within the CNS has been considered a therapeutic strategy [<xref ref-type="bibr" rid="CR90">90</xref>]. However, the potential of this therapeutic strategy has not yet been tried in migraine [<xref ref-type="bibr" rid="CR91">91</xref>].</p>
<p>To investigate central and peripheral serotonin turnover in neurological disorders and in depressed mood, researchers have adopted the tryptophan depletion technique (Acute Tryptophan Depletion ATD) [<xref ref-type="bibr" rid="CR82">82</xref>]. Initial studies in healthy volunteers showed that depletion of tryptophan is correlated with a decline in central serotonin turnover [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. The tryptophan-serotonin relationship has been confirmed in animal models [<xref ref-type="bibr" rid="CR94">94</xref>–<xref ref-type="bibr" rid="CR96">96</xref>] and was first demonstrated in 1970, indicating this mechanism may be potentially important in serotonin related pathologies in humans [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Changes in the composition of the blood plasma in the periphery can influence functioning of the nervous system and affect various serotonin-dependent brain functions and mood states like depression [<xref ref-type="bibr" rid="CR99">99</xref>–<xref ref-type="bibr" rid="CR101">101</xref>]. Changes in diet and nutrition can lead to changes in brain levels of the precursors for neurotransmitter synthesis and influence the rates at which neurons synthesize neurotransmitters [<xref ref-type="bibr" rid="CR101">101</xref>]. Tryptophan depletion increases nausea, headache and photophobia in migraine sufferers [<xref ref-type="bibr" rid="CR102">102</xref>]. Two studies in the 70s, tested L-tryptophan treatment in headache patients and reported headache indices were markedly lower with supplementation of L-tryptophan than with placebo [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. The utility of tryptophan for both research and clinical purposes has been underexplored. Further analysis of the relationship of plasma tryptophan with brain serotonin metabolism in both normal and diseased states will be beneficial to understanding the complex serotonergic biochemistry of migraine.</p>
</sec>
<sec id="FPar101">
<title>Tryptophan - Serotonin-melatonin pathway</title>
<p>Melatonin is a hormone that is synthesised at night-time from the precursor tryptophan in the pineal gland. Endogenous melatonin plays an important function in regulating circadian rhythms for proper sleep-wake cycles as well as many neuronal and hormonal functions [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. Multiple studies have demonstrated altered levels of melatonin secretion at night in the plasma or urine of migraine patients with cluster headache, migraine with and without aura, menstrual migraine, and chronic migraine relative to controls that spurred further investigation of melatonin as a prophylactic therapy [<xref ref-type="bibr" rid="CR107">107</xref>–<xref ref-type="bibr" rid="CR113">113</xref>]. Melatonin has also been found to be altered in other central nervous system (CNS) disorders, such as stroke, obsessive-compulsive disorder, mood and schizophrenia [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Melatonin has regulatory effects on gastrointestinal tract motility and sensation, has sleep promoting effects and mood regulation and anti-stress effects [<xref ref-type="bibr" rid="CR116">116</xref>]. Consequently, it is not surprising that melatonin supplements have shown potential in diminishing pain intensity in migraine co-morbid conditions such as fibromyalgia and irritable bowel syndrome [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>].</p>
<p>Melatonin has been considered to hold therapeutic properties on headache profiles due to its normalizing effects on circadian rhythms and sleep and was further pursued in controlled trials because it is non-toxic, low cost and easily available over the counter in most countries (see Table <xref ref-type="table" rid="Tab2">2</xref>) [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Bougea et al., [<xref ref-type="bibr" rid="CR120">120</xref>] conducted the longest trial lasting for a period of 6 months and demonstrated a positive effect in a children patient group. Studies on melatonin use in migraine have had some limitations, such as lack of adequate control and placebo, had a small sample size and throughout some of the trials the patients were permitted to take rescue medication for symptomatic relief of migraine during the trial period, limiting the comparisons that can be made. The future of melatonin-based therapy may also include melatonin receptor agonists and the design of trials with a longer follow up period, standardized designs, controls and IHS guidelines to establish the utility of melatonin-based therapy as a prophylactic therapy [<xref ref-type="bibr" rid="CR121">121</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of trials of melatonin-based therapy for migraine prophylaxis</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>Reference</th><th>Study design</th><th>Cases and migraine type</th><th>Daily dose and duration</th><th>Primary endpoint</th><th>Result</th></tr></thead><tbody><tr valign="top"><td>Peres et al., 2004 [<xref ref-type="bibr" rid="CR122">122</xref>]</td><td>open-labelled</td><td>Total adults, 32</td><td>3 mg/day, 30 min before bedtime for 3 months</td><td>Percentage of patients with &gt;50% reduction in migraine frequency</td><td>positive</td></tr><tr valign="top"><td>Miano et al., 2008 [<xref ref-type="bibr" rid="CR123">123</xref>]</td><td>open-labelled</td><td>Total children, 22<break></break>13 MO<break></break>1 MA<break></break>8 CTTH</td><td>3 mg/day for 3 months</td><td>Reduced the frequency of headache attacks<break></break>by &gt;50% from baseline</td><td>positive</td></tr><tr valign="top"><td>Alstadhaug et al., 2010 [<xref ref-type="bibr" rid="CR124">124</xref>]</td><td>randomized, double-blind, placebo-controlled crossover study</td><td>Total adults, 46<break></break>25 MO<break></break>13 MA</td><td>2 mg/day prolonged release melatonin, given 1 h before bedtime for 2 months</td><td>Migraine attack frequency (AF)</td><td>negative</td></tr><tr valign="top"><td>Fallah et al., 2015 [<xref ref-type="bibr" rid="CR125">125</xref>]</td><td>open-labelled, non-randomized, uncontrolled</td><td>Total children, 60<break></break>32 MO<break></break>28 MA</td><td>0.3 mg/kg for 3 months</td><td>Percentage of patients with &gt;50% reduction in migraine frequency</td><td>positive</td></tr><tr valign="top"><td>Bougea et al., 2016 [<xref ref-type="bibr" rid="CR120">120</xref>]</td><td>open-labelled</td><td>Total children, 41<break></break>12 TTH<break></break>37 M</td><td>4 mg/day 30 min before bedtime for 6 months</td><td>Reduced headache frequency</td><td>positive</td></tr></tbody></table><table-wrap-foot><p>
<italic>CCH</italic> chronic cluster headache, <italic>ECH</italic> episodic chronic headache, <italic>TTH</italic> tension-type headache, <italic>CTTH</italic> chronic tension-type headache, <italic>MA</italic> migraine with aura, <italic>MO</italic> migraine without aura, <italic>M</italic> migraine</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="FPar102">
<title>Tryptophan and tryptamine</title>
<p>Tryptamine is another functional neuromodulator produced from tryptophan metabolism and structurally related to serotonin [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR127">127</xref>]. D’Andrea et al., [<xref ref-type="bibr" rid="CR115">115</xref>] identified low levels of tryptamine in the plasma of 73 chronic migraine CM patients and 13 chronic tension-type headache (CTTH) patients relative to a group of 37 healthy subjects [<xref ref-type="bibr" rid="CR128">128</xref>]. In contrast the levels of circulating 5-HT and 5-HIAA were within normal range. The low tryptamine plasma levels found in CM and CTTH patients lead the authors to the conclusion that these two primary chronic headaches are characterized by “neurotransmitter and neuromodulator metabolic abnormalities in a hyperexcitable and hypoenergetic brain” due to insufficient serotonergic control of the pain threshold [<xref ref-type="bibr" rid="CR129">129</xref>]. The role of tryptophan and tyrosine metabolism in migraine headache is reviewed in D’Andrea et al., [<xref ref-type="bibr" rid="CR129">129</xref>–<xref ref-type="bibr" rid="CR131">131</xref>].</p>
</sec>
</sec>
<sec id="Sec8">
<title>PET imaging studies of serotonin</title>
<p>In the study of neurological disorders such as migraine, a recognizable limitation with investigating <italic>in vivo</italic> the biochemistry of CNS functioning is access to neuronal brain tissue of affected patients for controlled experimental study [<xref ref-type="bibr" rid="CR132">132</xref>]. In view of the non-existence of high-quality post-mortem brain tissue samples to study CNS functioning <italic>in vivo,</italic> peripheral blood is being proposed as a valid surrogate for genetic studies of migraine [<xref ref-type="bibr" rid="CR133">133</xref>], along with cerebrospinal fluid, saliva, platelets, plasma and urine to study neurotransmitter function. Given that migraine is a complex multi-faceted disorder, it makes sense to take a multi-dimensional approach that considers the whole organism.</p>
<p>The continued development and increasing availability of positron emission tomography (PET) and single positron emission computerized tomography (SPECT), and radio-ligands has enabled the study of serotonergic biology <italic>in vivo</italic> [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. Due to high sensitivity and better anatomic resolution, imaging techniques have provided an entry point to study perturbed functional networks in neurologic and psychiatric disorders [<xref ref-type="bibr" rid="CR136">136</xref>] and obtain more information about the distribution, density and activity of single receptor molecules in relation to migraine-specific actions of triptans [<xref ref-type="bibr" rid="CR137">137</xref>]. Three studies, have thus far employed the non-invasive method [<xref ref-type="bibr" rid="CR138">138</xref>] PET imaging using the tracer α-[<sup>11</sup>C] methyl-L tryptophan (<sup>11</sup>C-AMT) for measuring serotonin synthesis in the human brain [<xref ref-type="bibr" rid="CR139">139</xref>]. This method is based on the regional trapping of tracer <sup>11</sup>C-AMT concentration and uses <italic>in vivo</italic> measurements of <sup>11</sup>C-AMT plasma with reference to the brain trapping constant (K*, mL/g/minute) [<xref ref-type="bibr" rid="CR138">138</xref>]. Using this method, Chugani et al., [<xref ref-type="bibr" rid="CR127">127</xref>] reported a trend of elevated serotonin synthesis capacity in three female patients with MO after migraine patients were treated prophylactically with beta-adrenergic antagonists propranolol or nadolol, thought to be due to antagonism of the 5-HT1A receptor on serotonergic neurons [<xref ref-type="bibr" rid="CR140">140</xref>]. Additionally, two other PET studies demonstrated that serotonin receptors/transporters can be upregulated interictally (in between attacks) in migraine [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR142">142</xref>].</p>
<p>Sakai et al., performed a similar study in six migraine patients with PET imaging, scanning participants during an attack, after administering sumatriptan and in between attacks [<xref ref-type="bibr" rid="CR143">143</xref>]. Statistically significant changes were reported only in the migraine group treated with sumatriptan. Serotonin synthesis was significantly reduced, with a 33% reduced uptake of <sup>11</sup>C-AMT in a majority of brain regions, similar effects were also reported in rats [<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. The observed decrease in serotonin synthesis could be the body’s physiological adaptation to the presence of triptan which mimics the effect of serotonin. In a recent study, Sakai et al. tested the hypothesis of serotonergic dysfunction in migraine by scanning six female migraine subjects with MO at baseline and after oral administration of 40 mg of eletriptan, the triptan with the highest lipophilicity [<xref ref-type="bibr" rid="CR145">145</xref>]. In the migraine group who received eletriptan, a significantly reduced (16.3%) global K* value for serotonin was obtained in the migraine subjects in the interictal phase of their condition [<xref ref-type="bibr" rid="CR145">145</xref>]. Park et al., in a pilot study of eight female migraine patients investigated the availability of SERT in the brain stem and concluded that migraineurs who experience more painful headaches have lower serotonin neurotransmission and additionally reported an age-related decline of SERT availability [<xref ref-type="bibr" rid="CR146">146</xref>]. In summary, the results from these studies suggest that brain serotonin synthesis rate may be altered in migraineurs and that triptans are effective on pain pathways by decreasing brain serotonin synthesis.</p>
</sec>
<sec id="Sec9">
<title>Biochemical studies of serotonin in CSF and saliva</title>
<p>The underlying hypothesis motivating studies of CSF is that because CSF is in direct contact with the brain interstitial fluid, serotonin and biochemical changes in the brains of migraine patients may best be reflected in this fluid [<xref ref-type="bibr" rid="CR147">147</xref>]. Studies examining CSF are few, however, because they require spinal puncture, a costly and invasive procedure. Two studies, measuring serotonin activity in CSF can be found, one by Barrie et al., [<xref ref-type="bibr" rid="CR135">135</xref>] which indicated no change in 5HIAA levels in CSF of migraine patients with respect to the controls and [<xref ref-type="bibr" rid="CR148">148</xref>] one study by Kangasni et al., [<xref ref-type="bibr" rid="CR149">149</xref>] reported an increase in 5HIAA levels in CSF (see Table <xref ref-type="table" rid="Tab4">4</xref>).</p>
<p>Saliva has been used as a diagnostic tool to evaluate neurotransmitter function because it contains a variety of neuropeptides, integrating with the trigeminovascular and neuroendocrine systems [<xref ref-type="bibr" rid="CR150">150</xref>–<xref ref-type="bibr" rid="CR152">152</xref>]. There have been more studies trying to use saliva in the diagnostic and therapeutic assessment of migraine, e.g. the studies of Cady et al. [<xref ref-type="bibr" rid="CR153">153</xref>] and Bellamy et al. [<xref ref-type="bibr" rid="CR154">154</xref>] on CGRP in saliva of migraineurs. To date only one study by Marukawa et al., reported higher concentrations of serotonin and substance P in TTH patients [<xref ref-type="bibr" rid="CR155">155</xref>]. The clinical usefulness of saliva has not yet been established, additional studies may be able to develop protocols able to make use of this easily accessible fluid, perhaps through correct timing of sampling [<xref ref-type="bibr" rid="CR156">156</xref>].</p>
</sec>
<sec id="Sec10">
<title>Biochemical studies of serotonin in platelets</title>
<p>Interest in investigating platelets and peripheral biochemical factors is based on their interaction and proximity with the vascular endothelium. The vascular endothelium is a metabolically and physiologically active tissue that is semi-permeable and is important in regulating vascular tone [<xref ref-type="bibr" rid="CR157">157</xref>]. Neurotransmitters and other vasoactive agents capable of modulating the nerve and vascular systems are actively produced by the vascular endothelium and can disrupt endothelial function [<xref ref-type="bibr" rid="CR158">158</xref>]. Complex functional interactions that cause changes in endothelial function, vascular oxidative stress, promote platelet activation and enhance the inflammatory process can change the coagulant properties of blood producing alterations in neurovascular function and platelets may be an important part of these processes [<xref ref-type="bibr" rid="CR159">159</xref>–<xref ref-type="bibr" rid="CR162">162</xref>]. Attention has turned to the role of platelets in migraine due to the association and co-morbidity of migraine with several cerebrovascular disorders, including arterial dissection, ischemic stroke, and cardiovascular disease as well as the increased risk of thromboembolic events and the favourable effects of antiplatelet medication [<xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR164">164</xref>].</p>
<p>Platelets carry the largest reserve of serotonin which they capture from enterochromaffin cells [<xref ref-type="bibr" rid="CR165">165</xref>]. In the gastrointestinal tract, serotonin acts as a key signalling molecule mediating many GI functions, including peristalsis, secretion, vasodilation and perception of pain or nausea, vomiting, which are common symptoms experienced by migraineurs [<xref ref-type="bibr" rid="CR166">166</xref>–<xref ref-type="bibr" rid="CR168">168</xref>]. Additionally, platelets express SERT proteins (membrane-bound serotonin-selective reuptake transporter) that are identical to brain SERT [<xref ref-type="bibr" rid="CR169">169</xref>]. Due to its role in clearing serotonin from the synaptic cleft, SERT plays a central role in neurotransmission and a broad role in brain activity making it a sought after therapeutic target of multiple neuropsychiatric disorders [<xref ref-type="bibr" rid="CR170">170</xref>]. SERT knockout mice display notable reduction (60–80%) in serotonin concentration in several brain regions [<xref ref-type="bibr" rid="CR171">171</xref>] and markedly depleted serotonin tissue stores [<xref ref-type="bibr" rid="CR172">172</xref>–<xref ref-type="bibr" rid="CR174">174</xref>].</p>
<p>Numerous studies have found an association between migraine and a dysfunction in platelets (see Tables <xref ref-type="table" rid="Tab3">3</xref> and <xref ref-type="table" rid="Tab4">4</xref>). The platelet changes that have been described in migraineurs include increased platelet-to-platelet aggregation and up-regulation of platelet-leukocyte aggregates. Morphological differences in platelets of migraineurs reported include: 1) containing more ADP; 2) having more dense granules and; 3) showing qualitative differences in their serotonin release reaction and clumping [<xref ref-type="bibr" rid="CR175">175</xref>]. The contemporary literature is not conclusive on the relationship between platelet serotonin content and migraine however it generally agrees that the distorted behaviour of platelets presents with subtle changes in various functions (reviewed in [<xref ref-type="bibr" rid="CR176">176</xref>]). In a case study of two sisters with hemiplegic migraine, low levels of systemic serotonin, including the CSF serotonin metabolite 5-hydroxyindoleacetic acid and low platelet serotonin levels were described [<xref ref-type="bibr" rid="CR177">177</xref>]. Interestingly, administration of 5-hydroxytryptophan (a precursor of serotonin) and carbidopa ameliorated the sisters’ clinical symptoms.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Small scale biochemical studies of platelet serotonin in migraine patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>Reference</th><th>Substance</th><th>Material and methods</th><th>Cases/ Controls</th><th>Results</th></tr></thead><tbody><tr valign="top"><td>(Dalsgaard-Nielsen et al., 1974) [<xref ref-type="bibr" rid="CR210">210</xref>]</td><td>5-HT</td><td>5-HT in platelets estimated by Udenfriends method</td><td>M = 8<break></break>NC = 10</td><td>No change in the uptake or the endogenous release of 5-HT</td></tr><tr valign="top"><td>(Kalendovsky , 1975) [<xref ref-type="bibr" rid="CR211">211</xref>]</td><td>5-HT</td><td>Platelets from whole venous blood</td><td>M = 19<break></break>NC = 23</td><td>Migraine patients demonstrate platelet hyperaggregability more than normal subjects to all aggregating agents tested</td></tr><tr valign="top"><td>(Dvilansky et al., 1976) [<xref ref-type="bibr" rid="CR184">184</xref>]</td><td>5-HT</td><td>Platelets</td><td>MO = 22<break></break>MA = 16</td><td>Plasma during attacks released significantly more 5-HT</td></tr><tr valign="top"><td>(Muck-Seler et al., 1979)<break></break>[<xref ref-type="bibr" rid="CR212">212</xref>]</td><td>5-HT</td><td>Platelet poor-plasma (PPP) using spectrophotofluorimetric method of Crawford and Rudd</td><td>M = 24<break></break>NC = 25</td><td>Unchanged 5-HT platelet level during migraine attack</td></tr><tr valign="top"><td>(Rolf et al., 1981) [<xref ref-type="bibr" rid="CR213">213</xref>]</td><td>5-HT</td><td>Platelets</td><td>MCH = 23<break></break>NC = 20</td><td>↓ 5-HT observed in patients with muscle contraction headache</td></tr><tr valign="top"><td>(Carroll et al., 1982) [<xref ref-type="bibr" rid="CR214">214</xref>]</td><td>5-HT</td><td>Platelets</td><td>MO = 25<break></break>NC = 18</td><td>↓ reduced transport of 5-HT in platelets</td></tr><tr valign="top"><td>(Oxman et al., 1982) [<xref ref-type="bibr" rid="CR215">215</xref>]</td><td>5-HT</td><td>Platelets</td><td>M = 16<break></break>NC = 10</td><td>Membrane lipid composition may play a role in disease</td></tr><tr valign="top"><td>(Launay et al., 1982) [<xref ref-type="bibr" rid="CR216">216</xref>]</td><td>5-HT</td><td>Platelets</td><td>MO = 11<break></break>NC = 15</td><td>↓ Kinetic factor V<sub>max</sub> and <italic>K</italic>
<sub>m</sub>, PRP 5-HT levels</td></tr><tr valign="top"><td>(Pradalier et al., 1983) [<xref ref-type="bibr" rid="CR217">217</xref>]</td><td>5-HT</td><td>Platelets</td><td>MO = 19<break></break>NC = 15</td><td>Unconjugated serotonin concentration was decreased during the attacks and decrease in 5-HT uptake by platelets, with a fall in Km and Vmax</td></tr><tr valign="top"><td>(Kruglak et al., 1984) [<xref ref-type="bibr" rid="CR218">218</xref>]</td><td>5-HT</td><td>Platelets</td><td>M = 18<break></break>NC = 26</td><td>Increased aggregability during attacks</td></tr><tr valign="top"><td>(Lechner et al., 1985) [<xref ref-type="bibr" rid="CR219">219</xref>]</td><td>5-HT, EN, ADP</td><td>Optical density method</td><td>M =14<break></break>NC = 30</td><td>↑ enhanced platelet aggregation and platelet sensitivity in migraine patients</td></tr><tr valign="top"><td>(Lingjaerde, 1986) [<xref ref-type="bibr" rid="CR220">220</xref>]</td><td>5-HT</td><td>Platelets in platelet rich-plasma (PRP). This method measures Km and Vmax</td><td>MO = 14<break></break>MA = 10<break></break>NC = 25</td><td>The size of the granular compartment was larger for classic than for common migraine, and the efflux rate from compartment III was</td></tr><tr valign="top"><td>(Shukla et al., 1987) [<xref ref-type="bibr" rid="CR221">221</xref>]</td><td>5-HT</td><td>Platelets</td><td>TTH = 20<break></break>M = 19<break></break>NC = 15</td><td>↑ uptake of 5-HT in platelets</td></tr><tr valign="top"><td>(Kozubski et al., 1987) [<xref ref-type="bibr" rid="CR222">222</xref>]</td><td>5-HT</td><td>Platelets</td><td>M = 12<break></break>NC = 10</td><td>↑ Increased number and affinity of fibrinogen receptors on the platelet surface in migraineurs.</td></tr><tr valign="top"><td>(Joseph et al., 1988) [<xref ref-type="bibr" rid="CR223">223</xref>]</td><td>5-HT</td><td>Plasma</td><td>MO = 7<break></break>MA = 5<break></break>NC = 6</td><td>Abnormal sensitivity to PAF</td></tr><tr valign="top"><td>(D'Andrea et al., 1989a) [<xref ref-type="bibr" rid="CR224">224</xref>]</td><td>5-HT, DA, E, NE,</td><td>Platelets obtained from PRP from whole blood<break></break>HPLC colourimetric detection</td><td>MO = 19<break></break>MA = 9<break></break>NC = 15</td><td>High NE levels and low 5-HT/NE ratio in platelets of patients with MA platelet dense body hyposecretion</td></tr><tr valign="top"><td>(D'Andrea et al., 1989b) [<xref ref-type="bibr" rid="CR225">225</xref>]</td><td>5-HT</td><td>Platelets</td><td>MO = 19<break></break>MA = 9<break></break>NC = 15</td><td>Adhesion, surface activation, aggregation were investigated. Platelet dense bodies were increased. Increase in the content of serotonin, not evident in MA</td></tr><tr valign="top"><td>(Herman et al., 1989) [<xref ref-type="bibr" rid="CR226">226</xref>]</td><td>5-HT</td><td>Platelet aggregation was monitored using PRP, in a computerized four-channel aggregometer (CARAT)</td><td>M = 10<break></break>NC = 9</td><td>PAF may be involved in the 'pathogenesis of migraine and suggest that specific PAF receptor antagonists or synthesis blockers may help in the therapy of this disease</td></tr><tr valign="top"><td>(Takeshima et al., 1989) [<xref ref-type="bibr" rid="CR227">227</xref>]</td><td>5-HT</td><td>Cold pressor test. Blood was sampled three times through the three-way cock: before the stimulus, 1 min after the start of the stimulus, and 5 min after the start of the stimulus</td><td>MCH = 15<break></break>M = 13<break></break>NC = 14</td><td>Both PF4 and NE increased significantly, whereas FFA showed no remarkable changes. The increase of PF4, however, was independent of NE increase and FFA changes</td></tr><tr valign="top"><td>(Riddle et al., 1989) [<xref ref-type="bibr" rid="CR228">228</xref>]</td><td>5-HT</td><td>Electron microscope</td><td>MO = 21<break></break>MA = 15<break></break>NC = 15</td><td>Demonstrated structural alterations and increase in the number of dense bodies</td></tr><tr valign="top"><td>(Kovacs et al., 1990) [<xref ref-type="bibr" rid="CR179">179</xref>]</td><td>5-HT</td><td>Platelets in platelet rich-plasma (PRP)</td><td>MO = 17<break></break>MA = 14<break></break>NC = 13</td><td>Migraineurs have altered platelet aggregation properties and PAF may play a role. The EC50 value for ADP and platelet-activating factor were significantly higher.</td></tr><tr valign="top"><td>(Govitrapong et al., 1992) [<xref ref-type="bibr" rid="CR229">229</xref>]</td><td>5-HT</td><td>Platelets</td><td>M = 12<break></break>NC = 12</td><td>↓ in the maximal number of receptors (Bmax) on platelet membrane of migraine patients when compared to the normal healthy group</td></tr><tr valign="top"><td>(Cotrim et al., 1993) [<xref ref-type="bibr" rid="CR230">230</xref>]</td><td>5-HT</td><td>Platelet membrane fluidity was measured using the fluorescent probe TMA-DPH</td><td>MO = 11<break></break>MA = 20<break></break>NC = 17</td><td>Migraine have decreased membrane fluidity</td></tr><tr valign="top"><td>(Jensen, 1994) [<xref ref-type="bibr" rid="CR231">231</xref>]</td><td>5-HT</td><td>Platelet poor-plasma (PPP)</td><td>TTH = 13<break></break>NC = 29</td><td>Increased 5HT during attacks</td></tr><tr valign="top"><td>(Kitano et al., 1994) [<xref ref-type="bibr" rid="CR232">232</xref>]</td><td>5-HT</td><td>Platelets</td><td>MO = 19<break></break>MA = 10<break></break>TH = 22<break></break>NC = 27</td><td>↑ 11-dehydrothromboxane B2, platelet hyperfunction</td></tr><tr valign="top"><td>(Jarman et al., 1996) [<xref ref-type="bibr" rid="CR233">233</xref>]</td><td>5-HT</td><td>Platelets [<sup>14</sup>C]5HT release measured by Lingjaerde and Monstad method</td><td>M = 8<break></break>NC = 10</td><td>No change in release of platelet 5-HT</td></tr><tr valign="top"><td>(Fioroni et al., 1996) [<xref ref-type="bibr" rid="CR234">234</xref>]</td><td>5-HT, 5-HIAA, MAO-B</td><td>Platelets</td><td>M = 7<break></break>NC = 8</td><td>↓ reduced 5-HT and ↑ increased 5HIAA in luteal phase, suggesting a greater susceptibility</td></tr><tr valign="top"><td>(Srikiatkhachorn, 1996) [<xref ref-type="bibr" rid="CR235">235</xref>]</td><td>5-HT</td><td>Platelets in platelet rich-plasma (PRP)</td><td>M = 20<break></break>NC = 20</td><td>↓ Kinetic factor V<sub>max</sub> and <italic>K</italic>
<sub>m</sub>, = uptake of 5-HT</td></tr><tr valign="top"><td>(Pukhal'skaya et al., 1998) [<xref ref-type="bibr" rid="CR236">236</xref>]</td><td>5-HT</td><td>Platelets in platelet rich-plasma (PRP)</td><td>M = 8<break></break>NC = 8</td><td>5-HT transport systems in migraine patients and healthy donors are different</td></tr><tr valign="top"><td>(Oishi, 1998) [<xref ref-type="bibr" rid="CR237">237</xref>]</td><td>5-HT</td><td>Platelets</td><td>ETH = 10<break></break>CTH = 10<break></break>NC = 10</td><td>↑ platelet factor 4, D-thromboglobulin, thromboxane B, and 1 1-dehydrothromboxane B, concentrations in the plasma were significantly higher in the episodic tension- type headache group</td></tr><tr valign="top"><td>(Srikiatkhachorn, 1998) [<xref ref-type="bibr" rid="CR238">238</xref>]</td><td>5-HT</td><td>Platelets</td><td>M = 10<break></break>AAG = 10<break></break>NC = 10</td><td>Excessive use of analgesics depletes 5-HT from its storage sites and results in the hyposerotonergic state.</td></tr><tr valign="top"><td>(Sarchielli et al., 2004) [<xref ref-type="bibr" rid="CR239">239</xref>]</td><td>5-HT</td><td>Platelet-activating factor (PAF) HPLC radioimmunoassay method,<break></break>internal jugular venous blood</td><td>MO = 5</td><td>↑ production of PAF levels no change in activity of PAF acetyl-hydrolase (PAF-AH), enzyme involved in the catabolism of this phospholipid mediator, in migraine attacks</td></tr><tr valign="top"><td>(Yucel et al., 2014) [<xref ref-type="bibr" rid="CR240">240</xref>]</td><td>5-HT</td><td>Blood fibrinogen, D-dimer, galectin-3 determined by ELISA</td><td>M = 59<break></break>NC = 30</td><td>↑ levels of fibrinogen, D-dimer, galectin-3 in migraine patients<break></break>↑ higher D-dimer levels during migraine attacks may indicate hypercoagulability</td></tr></tbody></table><table-wrap-foot><p>
<italic>AAG</italic> Analgesic Abuse Group, <italic>CDH</italic> chronic daily headache, <italic>CH</italic> Cluster headache, <italic>CM</italic> complicated migraine, <italic>CMF</italic> chronic migraine with fibromyalgia, <italic>MA</italic> migraine with aura, <italic>MO</italic> migraine without aura, <italic>NC</italic> normal control, <italic>PAF</italic> platelet-activating factor, <italic>PPP</italic> platelet-poor plasma, <italic>PRP</italic> platelet-rich plasma, <italic>TH</italic> Tension headache; ↑ Increase; ↓ Decrease; = Unchanged</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Selected large scale biochemical studies of platelet serotonin in migraine patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>Reference</th><th>Substance</th><th>Material and methods</th><th>Cases/ controls</th><th>Results</th></tr></thead><tbody><tr valign="top"><td>(Couch, 1976) [<xref ref-type="bibr" rid="CR241">241</xref>]</td><td>5-HT</td><td>Platelet aggregation was tested to 1.7uM adenosine diphosphate employing light transmission methods modified after Born</td><td>M = 33<break></break>NC = 33</td><td>↑ platelet aggregability was measured by a) grading aggregation curves and b) by measuring percent disaggregation 3 min after peak aggregation was less</td></tr><tr valign="top"><td>(Couch, 1977) [<xref ref-type="bibr" rid="CR242">242</xref>]</td><td>5-HT</td><td>Platelets, optical density methods</td><td>M = 46<break></break>NC = 46</td><td>↑ migraine patients demonstrate platelet hyperaggregability, lower threshold for the platelet-release reaction and increased platelet stickiness following aggregation</td></tr><tr valign="top"><td>(Deshmuck, 1977) [<xref ref-type="bibr" rid="CR243">243</xref>]</td><td>5-HT</td><td>Platelets</td><td>M = 27<break></break>NC = 35</td><td>Platelet adhesiveness to glass beads and platelet aggregation response to ADP, epinephrine, thrombin and serotonin increased during the prodrome phase of migraine</td></tr><tr valign="top"><td>(Manotti et al., 1983) [<xref ref-type="bibr" rid="CR244">244</xref>]</td><td>5-HT</td><td>ADP induced platelet aggregation, ADP threshold concentration, platelet malondialdehyde production stimulated by thrombin, Beta-Thromboglobuli level in PPP</td><td>M = 30<break></break>NC = 30</td><td>Significant activation of platelet function</td></tr><tr valign="top"><td>(Waldenlind et al., 1985) [<xref ref-type="bibr" rid="CR245">245</xref>]</td><td>Platelets</td><td>Platelets</td><td>CH = 33<break></break>M = 34<break></break>NC = 50</td><td>↓ Kinetic factor V<sub>max</sub> and <italic>K</italic>
<sub>m</sub>, = uptake of 5-HT</td></tr><tr valign="top"><td>(Buttinelli et al., 1985) [<xref ref-type="bibr" rid="CR246">246</xref>]</td><td>5-HT</td><td>Platelet Aggregate Ratio (PAR) studied by Wu and Hoak’s technique</td><td>MO = 37<break></break>MA = 20<break></break>CM = 16<break></break>NC = 90</td><td>↑ circulating platelet aggregates</td></tr><tr valign="top"><td>(Walkowiak et al., 1989) [<xref ref-type="bibr" rid="CR247">247</xref>]</td><td>5-HT</td><td>Platelets and radioimmunoassay</td><td>MO = 34<break></break>NC = 28</td><td>Migraineurs have a higher receptor capacity for fibrinogen in platelets activated by ADP</td></tr><tr valign="top"><td>(Joseph et al., 1989) [<xref ref-type="bibr" rid="CR248">248</xref>]</td><td>5-HT</td><td>Platelets</td><td>M = 66<break></break>NC = 64</td><td>Increased number of dense bodies; altered coupling of 5-HT secretion from dense bodies and ionised calcium; decreased serotonin secretion.</td></tr><tr valign="top"><td>(Ribeiro et al., 1990) [<xref ref-type="bibr" rid="CR249">249</xref>]</td><td>5-HT, 5-HIAA</td><td>Serum serotonin (5-HT) measured by HPLC-EC</td><td>MO = 58<break></break>MA = 43<break></break>TH = 10<break></break>NC = 39</td><td>Significant decrease in Bmax, which suggests down-regulation of 5-HT2 receptors</td></tr><tr valign="top"><td>(Jha et al., 1992) [<xref ref-type="bibr" rid="CR250">250</xref>]</td><td>5-HT</td><td>Platelets</td><td>MA = 40</td><td>↑ platelet aggregation during the aura and headache phase of the migraine attack</td></tr><tr valign="top"><td>(Leira et al., 1993) [<xref ref-type="bibr" rid="CR251">251</xref>]</td><td>5-HT</td><td>Platelets in platelet rich-plasma (PRP)</td><td>TTH = 30<break></break>NC = 20</td><td>No change in PRP 5-HT levels</td></tr><tr valign="top"><td>(D'Andrea et al., 1994) [<xref ref-type="bibr" rid="CR178">178</xref>]</td><td>5-HT</td><td>Platelet-rich plasma (PRP)<break></break>Serotonin was measured by HPLC and platelet factor 4 (PF4) with an enzyme immunoassay kit</td><td>MO = 41<break></break>MA = 62<break></break>NC = 26</td><td>Increased basal platelet 5-HT and increased 5-HTsecretion induced by both collagen and</td></tr><tr valign="top"><td>(D'Andrea et al., 1995) [<xref ref-type="bibr" rid="CR252">252</xref>]</td><td>5-HT</td><td>Platelet-rich plasma (PRP)</td><td>MO = 41<break></break>MA = 62<break></break>TH = 28<break></break>NC = 26</td><td>Plasma and platelet 5-HT peak in MM in ovulatory phase; 5-HT peak evident in follicular phase in TH and controls.</td></tr><tr valign="top"><td>(Allais et al., 1997) [<xref ref-type="bibr" rid="CR253">253</xref>]</td><td>5-HT</td><td>Platelet aggregation was stimulated by ADP 1 μM during the luteal phase of the menstrual cycle in Menstrual migraine patients</td><td>MM = 46<break></break>NC = 27</td><td>↑ platelet aggregation during luteal phase of the menstrual cycle</td></tr><tr valign="top"><td>(Zeller et al., 2005) [<xref ref-type="bibr" rid="CR254">254</xref>]</td><td>5-HT</td><td>Platelets during attack free interval</td><td>MO = 48<break></break>MA = 25<break></break>NC = 72</td><td>MA patients ↑ numbers of aggregates<break></break>MO patients ↑ numbers of platelet-leucocyte aggregation and activation-dependent epitope expression</td></tr><tr valign="top"><td>(Taffi et al., 2005) [<xref ref-type="bibr" rid="CR255">255</xref>]</td><td>5-HT</td><td>Platelets in platelet rich-plasma (PRP). Membrane Na+/K + −ATPase activity and fluidity were determined with the fluorescent probes TMA-DPH and DPH</td><td>MO = 57<break></break>NC = 35</td><td>Migraine patients show intercritic changes in platelet membrane fluidity and activity that may be related to the oxidative stress caused by increased ONOO– levels</td></tr><tr valign="top"><td>(Yucel et al., 2014) [<xref ref-type="bibr" rid="CR240">240</xref>]</td><td>5-HT</td><td>Blood fibrinogen, D-dimer, galectin-3 determined by ELISA</td><td>M = 59<break></break>NC = 30</td><td>↑ levels of fibrinogen, D-dimer, galectin-3 in migraine patients<break></break>↑ higher D-dimer levels during migraine attacks may indicate hypercoagulability</td></tr></tbody></table><table-wrap-foot><p>
<italic>CH</italic> cluster headache, <italic>CM</italic> complicated migraine, <italic>MA</italic> migraine with aura, <italic>MM</italic> menstrual migraine, <italic>MO</italic> migraine without aura, <italic>PPP</italic> platelet-poor plasma, <italic>PRP</italic> platelet-rich plasma, <italic>TH</italic> Tension headache, <italic>NC</italic> normal control; ↑ Increase; ↓ Decrease; = Unchanged</p></table-wrap-foot></table-wrap>
</p>
<p>For the most part, investigations report increased platelet activation and it is argued that these changes could reflect parallel biochemical changes in the CNS (see Tables <xref ref-type="table" rid="Tab3">3</xref> and <xref ref-type="table" rid="Tab4">4</xref>). Patterns of platelet behaviour/activation have also been found to differ in migraine subgroups, a finding that could indicate different pathomechanisms [<xref ref-type="bibr" rid="CR178">178</xref>, <xref ref-type="bibr" rid="CR179">179</xref>]. There is, however, no platelet phenotype that can be used as a direct diagnostic biomarker for migraine [<xref ref-type="bibr" rid="CR180">180</xref>]. It is difficult to draw final conclusions for platelet biology studies in migraine as they have investigated different aspects of platelet biology and have at times reported contrasting results. The general state of affairs is that platelet anomalies are not considered to be causal for migraine and that this topic merits additional investigation to gain a fuller understanding [<xref ref-type="bibr" rid="CR181">181</xref>].</p>
</sec>
<sec id="Sec11">
<title>Biochemical studies of serotonin in plasma</title>
<p>Data regarding serotonin levels in plasma of migraineurs should be treated with caution due to differing definitions of plasma serotonin and determination of serotonin content in plasma. This is because normal blood plasma is composed of two distinguishable fractions namely platelet-rich-plasma (PRP) and platelet-poor plasma (PPP) [<xref ref-type="bibr" rid="CR182">182</xref>]. Platelet-rich-plasma is blood plasma that is mostly bound to platelets whereas platelet-poor plasma refers to the fraction of freely circulating serotonin which is said to be distinct to PRP. This fraction of blood plasma contains a very low number of platelets and is identified as the extraplatelet pool [<xref ref-type="bibr" rid="CR183">183</xref>]. This portion of plasma is difficult to assay consistently owing to the difficulty of preparing PPP without causing release of serotonin from platelets and without platelet contamination. Additionally, whether or not a study is using PPP or a less refined plasma subset is often unclear, adding to uncertainty [<xref ref-type="bibr" rid="CR183">183</xref>]. This is perhaps demonstrated in the contrasting results that have been obtained with a few studies reporting elevated levels of plasma serotonin, specifically studies by Dvilansky et al., 1976, Ferrari et al., 1989 and Milovanovic et al., 1999 [<xref ref-type="bibr" rid="CR184">184</xref>–<xref ref-type="bibr" rid="CR186">186</xref>] (see Tables <xref ref-type="table" rid="Tab3">3</xref> and <xref ref-type="table" rid="Tab4">4</xref>). Conversely studies by Curran et al., [<xref ref-type="bibr" rid="CR187">187</xref>], Rydzewski, [<xref ref-type="bibr" rid="CR188">188</xref>] and Nagata et al., [<xref ref-type="bibr" rid="CR189">189</xref>] reported lower levels of plasma serotonin in migraineurs than in controls during the attack. More consistency and standardised methods of assaying blood plasma in biochemical studies are required in order to move forward.</p>
</sec>
<sec id="Sec12">
<title>Biochemical studies of serotonin in urine</title>
<p>In addition to the studies examining serotonin metabolism in CSF, saliva, platelets and plasma there have been several studies using urine as a proxy for serotonin activity in the brain. These were often the first studies and were fundamental in highlighting a possible serotonin-dependent mechanism urging further investigation [<xref ref-type="bibr" rid="CR17">17</xref>]. Four out of seven independent studies observed an increase in the urinary excretion of the main metabolite of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), in association with migraine attacks [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR190">190</xref>, <xref ref-type="bibr" rid="CR177">177</xref>] (see Table <xref ref-type="table" rid="Tab5">5</xref>). Two studies [<xref ref-type="bibr" rid="CR186">186</xref>, <xref ref-type="bibr" rid="CR191">191</xref>] reported a decrease in urinary excretion of 5-HIAA and one study reported no difference [<xref ref-type="bibr" rid="CR192">192</xref>]. Bousser et al., [<xref ref-type="bibr" rid="CR191">191</xref>] provided evidence of a 31% lowered urinary 5-HIAA excretion in 44 young adult female migraine patients between attacks and in 33 healthy age- and sex-matched control subjects [<xref ref-type="bibr" rid="CR191">191</xref>]. Milovanovic et al., [<xref ref-type="bibr" rid="CR173">173</xref>] reported a similar trend of lowered urinary 5-HIAA excretion although the sample size in this study was smaller consisting of a total of 18 migraine patients [<xref ref-type="bibr" rid="CR186">186</xref>]. Despite urine’s ease of access, only a small number of studies have thus far investigated the biochemistry of urine in migraineurs.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Biochemical studies of 5-hydroxyindoleacetic acid (5-HIAA) in the urine of migraine patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>Reference</th><th>Migraine classification</th><th>Controls/cases</th><th>Sample tested</th><th>Levels</th><th>Controls/cases</th><th>Sample tested</th><th>Levels</th></tr></thead><tbody><tr valign="top"><td rowspan="2">(Sicuteri et al., 1961) [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td rowspan="2">Not reported</td><td>Controls: 15</td><td>Urine</td><td></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr valign="top"><td>M: 15</td><td></td><td>↑</td></tr><tr valign="top"><td rowspan="2">(Curran et al., 1965) [<xref ref-type="bibr" rid="CR187">187</xref>]</td><td rowspan="2">Not reported</td><td>Controls: 10</td><td>Urine</td><td></td><td>Controls: 21</td><td>Plasma</td><td></td></tr><tr valign="top"><td>M: 18</td><td></td><td>↑</td><td>M: 11</td><td></td><td>↓</td></tr><tr valign="top"><td rowspan="2">(Curzon et al., 1966) [<xref ref-type="bibr" rid="CR149">149</xref>]</td><td rowspan="2">Not reported</td><td>Controls: 4</td><td>Urine</td><td></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr valign="top"><td>M: 9</td><td></td><td>=</td></tr><tr valign="top"><td rowspan="2">(Kangasni et al., 1972) [<xref ref-type="bibr" rid="CR149">149</xref>]</td><td rowspan="2">Not reported</td><td>Controls: 6</td><td>Urine</td><td></td><td>Controls: 6</td><td>CSF</td><td></td></tr><tr valign="top"><td>M: 9</td><td></td><td>↑</td><td>M: 14</td><td></td><td>↑</td></tr><tr valign="top"><td rowspan="2">(Deanovic et al., 1975) [<xref ref-type="bibr" rid="CR190">190</xref>]</td><td rowspan="2">(Headache, 1962) [<xref ref-type="bibr" rid="CR193">193</xref>]</td><td>Controls: 4</td><td>Urine</td><td></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr valign="top"><td>M: 14</td><td></td><td>↑</td></tr><tr valign="top"><td rowspan="2">(Bousser et al., 1986) [<xref ref-type="bibr" rid="CR191">191</xref>]</td><td rowspan="2">(Headache, 1970) [<xref ref-type="bibr" rid="CR194">194</xref>]</td><td>Controls: 33</td><td>Urine</td><td></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr valign="top"><td>M: 44</td><td></td><td>↓</td></tr><tr valign="top"><td rowspan="3">(Milovanovic et al., 1999) [<xref ref-type="bibr" rid="CR186">186</xref>]</td><td rowspan="3">(ICHD-I, 1988) [<xref ref-type="bibr" rid="CR195">195</xref>]</td><td>Controls: 11</td><td>Urine</td><td></td><td>Controls: 5</td><td>Plasma</td><td></td></tr><tr valign="top"><td>M: 8</td><td></td><td>↓</td><td>M: 5</td><td></td><td>↑</td></tr><tr valign="top"><td>TTH: 10</td><td></td><td>↓</td><td>TTH: 7</td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>
<italic>M</italic> migraine, <italic>CSF</italic> cerebrospinal fluid, <italic>TTH</italic> Tension-Type Headache; ↑ Increase; ↓ Decrease; = Unchanged</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec13">
<title>Biochemical model of serotonin</title>
<p>The existing data support the premise that serotonin is low interictally but increased ictally (during attacks themselves) in the migraine brain [<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR196">196</xref>]. According to this model, during an attack serotonin is released from platelets into blood plasma causing a short-lived increase in free plasma serotonin that raises serotonin levels in the brain [<xref ref-type="bibr" rid="CR197">197</xref>]. The second arm of the model posits that raised levels of serotonin in the brain, during a migraine attack, exerts a vasoconstrictor effect on intracerebral arteries initiating the aura phase and cerebral ischemia with resulting visual disturbances. The concentration of serotonin eventually lowers because serotonin is broken down and excreted and this lowering post-attack is thought to produce vasodilation of extracerebral arteries causing headache and pain [<xref ref-type="bibr" rid="CR197">197</xref>]. Migraine is generally regarded as a low serotonin syndrome. Diminished levels of serotonin in the brain lower the threshold for pain and are evident in some disorders co-morbid with migraine including chronic tension headache [<xref ref-type="bibr" rid="CR198">198</xref>] and depression [<xref ref-type="bibr" rid="CR199">199</xref>] as well as other chronic diseases such as fibromyalgia, irritable bowel syndrome [<xref ref-type="bibr" rid="CR200">200</xref>], premenstrual dysphoric disorder and depression. In addition, tricyclic antidepressants can also reduce the frequency of migraine attacks by increasing serotonin signalling further supporting a role for serotonin in the pathobiology of migraine [<xref ref-type="bibr" rid="CR201">201</xref>]. Serotonin has also been implicated in CSD and the trigeminovascular pathway. Experimental depletion of serotonin in rats, enhances the development of CSD with accompanying cerebrovascular changes and increases responsiveness and sensitivity of the trigeminal system [<xref ref-type="bibr" rid="CR202">202</xref>–<xref ref-type="bibr" rid="CR204">204</xref>].</p>
<p>Metabolomics is an emerging field that has recently shown that variations in brain metabolic homeostasis are associated with neurological disorders [<xref ref-type="bibr" rid="CR205">205</xref>, <xref ref-type="bibr" rid="CR206">206</xref>]. In particular a recent study by Shyti et al., [<xref ref-type="bibr" rid="CR191">191</xref>] identified metabolic changes by mass spectrometry in a transgenic mouse model of hemiplegic migraine after experimentally induced CSD [<xref ref-type="bibr" rid="CR207">207</xref>]. This is the first study demonstrating CSD-induced metabolite differences in Familial Hemiplegic Migraine type 1 R192Q mice relative to WT mice and that these events can be captured beyond the CNS in plasma samples. Although we still do not know what the connection of central and peripheral serotonergic changes in migraine may be, further study based on metabolic profiling of biological fluids which contain the “products of numerous genome-wide and proteome-wide interactions” [<xref ref-type="bibr" rid="CR208">208</xref>], the ‘metabolome’ [<xref ref-type="bibr" rid="CR209">209</xref>] will continue to shed light on the inner workings of the migraine brain. To study serotonin deficiency-associated mechanisms a study by Weng et al., used a metabolomics approach to identify biomarkers from serotonin deficient mice [<xref ref-type="bibr" rid="CR47">47</xref>]. The mice were depleted of serotonin via two approaches (1) use of p-chlorophenylalanine (pCPA) to pharmacologically inhibit tryptophan hydroxylase (Tph), a rate-limiting enzyme in serotonin biosynthesis and (2) genetic knockout of the Tph2 isoform. In this study serotonin deficiency was associated with altered energy metabolism and several biomarkers were identified in the serotonin deficient mice to be significantly altered compared with the control mice [<xref ref-type="bibr" rid="CR47">47</xref>]. Moreover, the combination of sensitive brain imaging techniques and metabolomics platforms hold optimism to identify novel metabolite-gene relationships and new insight into small molecular changes in neuronal metabolism to enhance our understanding of biochemical pathways “functional readout”. Pharmacometabolomics-informed pharmacogenomics studies will therefore occupy an important position in the coming tide of molecular and “omics” research.</p>
</sec>
</sec>
</sec>
<sec id="Sec14">
<title>Conclusion</title>
<p>The evidence so far points to migraine as a biochemically complex disorder involving several neurotransmitter systems which converge in their synaptic pathways. The general trend observed is that migraine patients have alterations of neurotransmitters in biological fluids with different biochemistry from controls, however the interpretation of the biological significance of these peripheral changes is unresolved. At present, despite the observation of biochemical alterations, specific diagnostic markers are lacking for this disorder. In addition MA and MO sufferers may exhibit varying degrees and types of neurotransmitter dysfunction due to differing neurological features of both migraine types which may be related to the aetiology and underlying genetic component of each migraine subtype. Insufficient serotonergic input due to changes in synthesis, release, receptor function/expression, reuptake and transport in the brain and throughout the body may contribute to vulnerability to migraine. Genetic studies have highlighted involvement of the serotonin transporter gene SERT in migraine susceptibility. However, serotonergic biochemistry is complex and evidently a multiplicity of factors, rather than any single one, combine to result in migraine phenotypes. More research is required to shed light on the course of these various biochemical phenomena and enable more robust conclusions on causal relationships. The absence of modern biochemical studies underscores the need for more rigorously conducted research utilizing larger sample sizes, updated IHS classification criteria and more sensitive bioassays and instruments and standardized methods for sample collection, preparation/analysis. Novel approaches for investigating the serotonergic system using PET imaging technology integrated with a metabolomics and systems biology platform may help to better understand the biochemical milieu and metabolome of migraineurs and establish if the biochemical changes are linked to the clinical presentation of the disease process. In conclusion, given the therapeutic efficacy of triptans, investigating the functionality of the serotonergic system in the migraine brain remains on the agenda to illuminate disease pathomechanisms and new lines of treatment to enable a superior understanding of the disease process that will further aid in the diagnosis, treatment and management of migraine and headache related disorders.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>5-HIAA</term>
<def>
<p>5-hydroxyindoleacetic acid</p>
</def>
</def-item>
<def-item>
<term>AAG</term>
<def>
<p>Analgesic abuse group</p>
</def>
</def-item>
<def-item>
<term>CDH</term>
<def>
<p>Chronic daily headache</p>
</def>
</def-item>
<def-item>
<term>CH</term>
<def>
<p>Cluster headache</p>
</def>
</def-item>
<def-item>
<term>CM</term>
<def>
<p>Complicated migraine</p>
</def>
</def-item>
<def-item>
<term>CMF</term>
<def>
<p>Chronic migraine with fibromyalgia</p>
</def>
</def-item>
<def-item>
<term>CSD</term>
<def>
<p>Cortical spreading depression</p>
</def>
</def-item>
<def-item>
<term>CSF</term>
<def>
<p>Cerebrospinal fluid</p>
</def>
</def-item>
<def-item>
<term>MA</term>
<def>
<p>Migraine with aura</p>
</def>
</def-item>
<def-item>
<term>MM</term>
<def>
<p>Menstrual migraine</p>
</def>
</def-item>
<def-item>
<term>MO</term>
<def>
<p>Migraine without aura</p>
</def>
</def-item>
<def-item>
<term>NC</term>
<def>
<p>Normal control</p>
</def>
</def-item>
<def-item>
<term>PPP</term>
<def>
<p>Platelet-poor plasma</p>
</def>
</def-item>
<def-item>
<term>PRP</term>
<def>
<p>Platelet-rich plasma</p>
</def>
</def-item>
<def-item>
<term>TH</term>
<def>
<p>Tension headache</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>Claudia Gasparini was the recipient of a Griffith University Postgraduate scholarship. We dedicate this review to pay tribute to Federigo Sicuteri for his seminal contribution to migraine research.</p>
<sec id="FPar1">
<title>Authors’ contributions</title>
<p>CG conceived and designed the review, drafted the manuscript and revised it for intellectual content. RS and LG revised the manuscript for intellectual content and provided essential comments to finalize the manuscript. All authors read and approved the final manuscript.</p>
</sec>
<sec id="FPar2">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar3">
<title>Consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec id="FPar4">
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vos</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Flaxman</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Naghavi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Michaud</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ezzati</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shibuya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Salomon</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Abdalla</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aboyans</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ackerman</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Alvarado</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Atkinson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Baddour</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Bahalim</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Barker-Collo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barrero</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Bartels</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Basanez</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bernabe</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bhalla</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bhandari</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bikbov</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bin Abdulhak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Birbeck</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Blencowe</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Blore</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Blyth</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bolliger</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bonaventure</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boufous</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bourne</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Boussinesq</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Braithwaite</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Brayne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bridgett</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brooker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brugha</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Bryan-Hancock</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bucello</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Buchbinder</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Buckle</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Budke</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Burch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Burney</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Burstein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Calabria</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Canter</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Carabin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Carapetis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Carmona</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cella</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Charlson</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chugh</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Coffeng</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Colan</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Colquhoun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Colson</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Condon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Corriere</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cortinovis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Vaccaro</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Couser</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cowie</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Criqui</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dabhadkar</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Dahiya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dahodwala</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Damsere-Derry</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Danaei</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Leo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Degenhardt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dellavalle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Delossantos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Denenberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Derrett</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Des Jarlais</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Dharmaratne</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Dherani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Diaz-Torne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dolk</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dorsey</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Driscoll</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Duber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ebel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Edmond</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Elbaz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Erskine</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Erwin</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Espindola</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ewoigbokhan</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Farzadfar</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Feigin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Felson</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferri</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Fevre</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Finucane</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Flaxman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Flood</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Foreman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Forouzanfar</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Fowkes</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fransen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Gabbe</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Gabriel</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Gakidou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ganatra</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gaspari</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gillum</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Gmel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gosselin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Grainger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Groeger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gunnell</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Haagsma</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hagan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Halasa</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Haring</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Haro</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Havmoeller</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Higashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hoen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hotez</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hoy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Ibeanusi</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Jarvis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jasrasaria</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jayaraman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Johns</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jonas</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Karthikeyan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kassebaum</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Keren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Khoo</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>King</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Knowlton</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Kobusingye</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Koranteng</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krishnamurthi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lalloo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Laslett</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Lathlean</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Leasher</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Leigh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Limb</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Lipnick</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lipshultz</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Loane</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Lyons</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mabweijano</surname>
<given-names>J</given-names>
</name>
<name>
<surname>MacIntyre</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Malekzadeh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mallinger</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Manivannan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marcenes</surname>
<given-names>W</given-names>
</name>
<name>
<surname>March</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Margolis</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matsumori</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Matzopoulos</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mayosi</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>McAnulty</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>McGill</surname>
<given-names>N</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Medina-Mora</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mensah</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Merriman</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Miglioli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Mocumbi</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Moffitt</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Mokdad</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Monasta</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Montico</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moradi-Lakeh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morawska</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Murdoch</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Mwaniki</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Naidoo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Naldi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Narayan</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Nevitt</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Nolte</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>O’Donnell</surname>
<given-names>M</given-names>
</name>
<name>
<surname>O’Hanlon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Olives</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Omer</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Ortblad</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ozgediz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Page</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pahari</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pandian</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Rivero</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Patten</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Padilla</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Perez-Ruiz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Perico</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pesudovs</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Pierce</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pion</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Polanczyk</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Polinder</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pope</surname>
<given-names>CA</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Popova</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Porrini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pourmalek</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Prince</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pullan</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Ramaiah</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Ranganathan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Razavi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rehm</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Rein</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Remuzzi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rivara</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>De Leon</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Ronfani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Room</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Rushton</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Sanchez-Riera</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sanman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schwebel</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Segui-Gomez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shahraz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shepard</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shivakoti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sleet</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Sliwa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Stapelberg</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Steer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stolk</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Stovner</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Sudfeld</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Syed</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tamburlini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tavakkoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Thurston</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Tleyjeh</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Tonelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Towbin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Truelsen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tsilimbaris</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Ubeda</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Undurraga</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>van der Werf</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>van Os</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vavilala</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Venketasubramanian</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Watt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Weatherall</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Weinstock</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Weisskopf</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Weissman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>White</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Whiteford</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wiersma</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Witt</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Woolf</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Wulf</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Zaidi</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Zonies</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>AlMazroa</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Memish</surname>
<given-names>ZA</given-names>
</name>
</person-group>
<article-title>Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010</article-title>
<source/>Lancet
          <year>2012</year>
<volume>380</volume>
<issue>9859</issue>
<fpage>2163</fpage>
<lpage>2196</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61729-2</pub-id>
<pub-id pub-id-type="pmid">23245607</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>IHS</collab>
</person-group>
<article-title>The international classification of headache disorders, 3rd edition (beta version)</article-title>
<source/>Cephalalgia
          <year>2013</year>
<volume>33</volume>
<issue>9</issue>
<fpage>629</fpage>
<lpage>808</lpage>
<pub-id pub-id-type="doi">10.1177/0333102413485658</pub-id>
<pub-id pub-id-type="pmid">23771276</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stovner</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Hagen</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Prevalence, burden, and cost of headache disorders</article-title>
<source/>Curr Opin Neurol
          <year>2006</year>
<volume>19</volume>
<issue>3</issue>
<fpage>281</fpage>
<lpage>285</lpage>
<pub-id pub-id-type="doi">10.1097/01.wco.0000227039.16071.92</pub-id>
<pub-id pub-id-type="pmid">16702836</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malone</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Bhowmick</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wachholtz</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>Migraine: treatments, comorbidities, and quality of life, in the USA</article-title>
<source/>J Pain Res
          <year>2015</year>
<volume>8</volume>
<fpage>537</fpage>
<lpage>547</lpage>
<pub-id pub-id-type="doi">10.2147/JPR.S88207</pub-id>
<pub-id pub-id-type="pmid">26316804</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buse</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Loder</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Gorman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Reed</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Fanning</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>RB</given-names>
</name>
</person-group>
<article-title>Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American migraine prevalence and prevention (AMPP) study</article-title>
<source/>Headache
          <year>2013</year>
<volume>53</volume>
<issue>8</issue>
<fpage>1278</fpage>
<lpage>1299</lpage>
<pub-id pub-id-type="doi">10.1111/head.12150</pub-id>
<pub-id pub-id-type="pmid">23808666</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasparini</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Sutherland</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>LR</given-names>
</name>
</person-group>
<article-title>Studies on the pathophysiology and genetic basis of migraine</article-title>
<source/>Curr Genomics
          <year>2013</year>
<volume>14</volume>
<issue>5</issue>
<fpage>300</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.2174/13892029113149990007</pub-id>
<pub-id pub-id-type="pmid">24403849</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vecsei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Majlath</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Balog</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tajti</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Drug targets of migraine and neuropathy: treatment of hyperexcitability</article-title>
<source/>CNS Neurol Disord Drug Targets
          <year>2015</year>
<volume>14</volume>
<issue>5</issue>
<fpage>664</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="doi">10.2174/1871527314666150429114040</pub-id>
<pub-id pub-id-type="pmid">25921739</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<mixed-citation publication-type="other">Costa C, Tozzi A, Rainero I, Cupini LM, Calabresi P, Ayata C, Sarchielli P (2013) Cortical spreading depression as a target for anti-migraine agents. J Head Pain 14. doi:10.1186/1129-2377-14-62.</mixed-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burstein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jakubowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>SD</given-names>
</name>
</person-group>
<article-title>The science of migraine</article-title>
<source/>J Vestib Res
          <year>2011</year>
<volume>21</volume>
<issue>6</issue>
<fpage>305</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="pmid">22348935</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aggarwal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Puri</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Puri</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Serotonin and CGRP in migraine</article-title>
<source/>Ann Neurosci
          <year>2012</year>
<volume>19</volume>
<issue>2</issue>
<fpage>88</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.5214/ans.0972.7531.12190210</pub-id>
<pub-id pub-id-type="pmid">25205974</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<mixed-citation publication-type="other">Persico AM, Verdecchia M, Pinzone V, Guidetti V (2014) Migraine genetics: current findings and future lines of research. Neurogenetics. doi:10.1007/s10048-014-0433-x.</mixed-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Spitzer</surname>
<given-names>NC</given-names>
</name>
</person-group>
<article-title>Calcium signaling in neuronal development</article-title>
<source/>Cold Spring Harb Perspect Biol
          <year>2011</year>
<volume>3</volume>
<issue>10</issue>
<fpage>a004259</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a004259</pub-id>
<pub-id pub-id-type="pmid">21730044</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<mixed-citation publication-type="other">Daubert EA, Condron BG Serotonin: a regulator of neuronal morphology and circuitry. Trends Neurosci 33 (9):424–434. doi:10.1016/j.tins.2010.05.005</mixed-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dallel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Artola</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Monconduit</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>General trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progression</article-title>
<source/>Pain
          <year>2014</year>
<volume>155</volume>
<issue>7</issue>
<fpage>1196</fpage>
<lpage>1205</lpage>
<pub-id pub-id-type="doi">10.1016/j.pain.2014.03.001</pub-id>
<pub-id pub-id-type="pmid">24631586</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dussor</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Ion channels and migraine</article-title>
<source/>Headache
          <year>2014</year>
<volume>54</volume>
<issue>4</issue>
<fpage>619</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="doi">10.1111/head.12323</pub-id>
<pub-id pub-id-type="pmid">24697223</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedrich</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tavraz</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Junghans</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>ATP1A2 mutations in migraine: seeing through the facets of an Ion pump onto the neurobiology of disease</article-title>
<source/>Front Physiol
          <year>2016</year>
<volume>7</volume>
<fpage>239</fpage>
<pub-id pub-id-type="pmid">27445835</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sicuteri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Anselmi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Testi</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Biochemical investigations in headache: increase in hydroxyindoleactic acid excretion during migraine attacks</article-title>
<source/>Int Arch Allergy Appl Immunol
          <year>1961</year>
<volume>19</volume>
<issue>1</issue>
<fpage>55</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1159/000229194</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoyer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hannon</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Molecular, pharmacological and functional diversity of 5-HT receptors</article-title>
<source/>Pharmacol Biochem Behav
          <year>2002</year>
<volume>71</volume>
<issue>4</issue>
<fpage>533</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1016/S0091-3057(01)00746-8</pub-id>
<pub-id pub-id-type="pmid">11888546</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gothert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schlicker</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Classification of serotonin receptors</article-title>
<source/>J Cardiovasc Pharmacol
          <year>1987</year>
<volume>10</volume>
<issue>Suppl 3</issue>
<fpage>S3</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1097/00005344-198706103-00003</pub-id>
<pub-id pub-id-type="pmid">2446065</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<mixed-citation publication-type="other">Usman HO, Balaban CD (2016) Distribution of 5-HT1F Receptors in Monkey Vestibular and Trigeminal Ganglion Cells. Frontiers in Neurology 7 (173). doi:10.3389/fneur.2016.00173</mixed-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Booij</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Szyf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Benkelfat</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Genetic and early environmental influences on the serotonin system: consequences for brain development and risk for psychopathology</article-title>
<source/>J Psychiatry Neurosci
          <year>2015</year>
<volume>40</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1503/jpn.140099</pub-id>
<pub-id pub-id-type="pmid">25285876</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Heils</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Serotonergic gene transcriptional control regions: targets for antidepressant drug development?</article-title>
<source/>int j neuropsychopharmacol
          <year>2000</year>
<volume>3</volume>
<issue>1</issue>
<fpage>67</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145700001747</pub-id>
<pub-id pub-id-type="pmid">11343581</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordquist</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Oreland</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Serotonin, genetic variability, behaviour, and psychiatric disorders--a review</article-title>
<source/>Ups J Med Sci
          <year>2010</year>
<volume>115</volume>
<issue>1</issue>
<fpage>2</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.3109/03009730903573246</pub-id>
<pub-id pub-id-type="pmid">20187845</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collier</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Stober</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Heils</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Catalano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Di Bella</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Arranz</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Vallada</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Bengel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Smeraldi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kirov</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sham</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders</article-title>
<source/>Mol Psychiatry
          <year>1996</year>
<volume>1</volume>
<issue>6</issue>
<fpage>453</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="pmid">9154246</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heils</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Teufel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Petri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stober</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Riederer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bengel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Allelic variation of human serotonin transporter gene expression</article-title>
<source/>J Neurochem
          <year>1996</year>
<volume>66</volume>
<issue>6</issue>
<fpage>2621</fpage>
<lpage>2624</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1996.66062621.x</pub-id>
<pub-id pub-id-type="pmid">8632190</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabol</surname>
<given-names>SZ</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A functional polymorphism in the monoamine oxidase a gene promoter</article-title>
<source/>Hum Genet
          <year>1998</year>
<volume>103</volume>
<issue>3</issue>
<fpage>273</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1007/s004390050816</pub-id>
<pub-id pub-id-type="pmid">9799080</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schurks</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rist</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>STin2 VNTR polymorphism in the serotonin transporter gene and migraine: pooled and meta-analyses</article-title>
<source/>J Headache Pain
          <year>2010</year>
<volume>11</volume>
<issue>4</issue>
<fpage>317</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="doi">10.1007/s10194-010-0230-3</pub-id>
<pub-id pub-id-type="pmid">20585826</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>SP</given-names>
</name>
</person-group>
<article-title>Association of 5-HTT gene polymorphisms with migraine: a systematic review and meta-analysis</article-title>
<source/>J Neurol Sci
          <year>2011</year>
<volume>J Neurol Sci 305</volume>
<issue>1–2</issue>
<fpage>57</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2011.03.016</pub-id>
<pub-id pub-id-type="pmid">21450309</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schurks</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rist</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>5-HTTLPR polymorphism in the serotonin transporter gene and migraine: a systematic review and meta-analysis</article-title>
<source/>Cephalalgia
          <year>2010</year>
<volume>30</volume>
<issue>11</issue>
<fpage>1296</fpage>
<lpage>1305</lpage>
<pub-id pub-id-type="doi">10.1177/0333102410362929</pub-id>
<pub-id pub-id-type="pmid">20959425</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yilmaz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Erdal</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Herken</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cataloluk</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Barlas</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Bayazit</surname>
<given-names>YA</given-names>
</name>
</person-group>
<article-title>Significance of serotonin transporter gene polymorphism in migraine</article-title>
<source/>J Neurol Sci
          <year>2001</year>
<volume>186</volume>
<issue>1–2</issue>
<fpage>27</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-510X(01)00491-9</pub-id>
<pub-id pub-id-type="pmid">11412868</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juhasz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zsombok</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Laszik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gonda</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sotonyi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Faludi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bagdy</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Association analysis of 5-HTTLPR variants, 5-HT2a receptor gene 102 T/C polymorphism and migraine</article-title>
<source/>J Neurogenet
          <year>2003</year>
<volume>17</volume>
<issue>2–3</issue>
<fpage>231</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1080/714049416</pub-id>
<pub-id pub-id-type="pmid">14668201</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borroni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brambilla</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liberini</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Archetti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gipponi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Volta</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Padovani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Functional serotonin 5-HTTLPR polymorphism is a risk factor for migraine with aura</article-title>
<source/>J Headache Pain
          <year>2005</year>
<volume>6</volume>
<issue>4</issue>
<fpage>182</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1007/s10194-005-0179-9</pub-id>
<pub-id pub-id-type="pmid">16362658</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marziniak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mossner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Sommer</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>A functional serotonin transporter gene polymorphism is associated with migraine with aura</article-title>
<source/>Neurology
          <year>2005</year>
<volume>64</volume>
<issue>1</issue>
<fpage>157</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000148597.52312.9E</pub-id>
<pub-id pub-id-type="pmid">15642926</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Todt</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Freudenberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goebel</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Heinze</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heinze-Kuhn</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rietschel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gobel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kubisch</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Variation of the serotonin transporter gene SLC6A4 in the susceptibility to migraine with aura</article-title>
<source/>Neurology
          <year>2006</year>
<volume>67</volume>
<issue>9</issue>
<fpage>1707</fpage>
<lpage>1709</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000242883.96822.93</pub-id>
<pub-id pub-id-type="pmid">17101915</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corominas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sobrido</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ribases</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cuenca-Leon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Blanco-Arias</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Narberhaus</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Roig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leira</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lopez-Gonzalez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Macaya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cormand</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Association study of the serotoninergic system in migraine in the Spanish population</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2010</year>
<volume>153B</volume>
<issue>1</issue>
<fpage>177</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="pmid">19455600</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogilvie</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Dhall</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Battersby</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ulrich</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Harmar</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Olesen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura</article-title>
<source/>Cephalalgia
          <year>1998</year>
<volume>18</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1998.1801023.x</pub-id>
<pub-id pub-id-type="pmid">9601620</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Meta-analysis of 5-hydroxytryptamine type 2A receptor polymorphisms and migraine susceptibility</article-title>
<source/>Int J Neurosci
          <year>2014</year>
<volume>124</volume>
<issue>12</issue>
<fpage>882</fpage>
<lpage>889</lpage>
<pub-id pub-id-type="doi">10.3109/00207454.2014.888425</pub-id>
<pub-id pub-id-type="pmid">25019276</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gormley</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Anttila</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Winsvold</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Palta</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Esko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pers</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Farh</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Cuenca-Leon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Muona</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Furlotte</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ingason</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ligthart</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Terwindt</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kallela</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Freilinger</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Stam</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Borck</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Koiranen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Quaye</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Lehtimaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sarin</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Wedenoja</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hinds</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Buring</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Schurks</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Hrafnsdottir</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Stefansson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ring</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Hottenga</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Penninx</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Farkkila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Artto</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kaunisto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vepsalainen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Madden</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Kurki</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Kals</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Magi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Parn</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hamalainen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Byrnes</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Franke</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stergiakouli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Sandor</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Webber</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cader</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Muller-Myhsok</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meitinger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Salomaa</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Heikkila</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Loehrer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Uitterlinden</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Hofman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Duijn</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Cherkas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Stubhaug</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Mannikko</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mihailov</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Milani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gobel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Esserlind</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Werge</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kaprio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aromaa</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Raitakari</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ikram</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Spector</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jarvelin</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Metspalu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kubisch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Strachan</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Belin</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Dichgans</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wessman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van den Maagdenberg</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Zwart</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Boomsma</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Stefansson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Olesen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chasman</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Nyholt</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Palotie</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine</article-title>
<source/>Nat Genet
          <year>2016</year>
<volume>48</volume>
<issue>8</issue>
<fpage>856</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3598</pub-id>
<pub-id pub-id-type="pmid">27322543</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Noble-Topham</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Percy</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Ebers</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Chromosome 1p36 in migraine with aura: association study of the 5HT(1D) locus</article-title>
<source/>Neuroreport
          <year>2012</year>
<volume>23</volume>
<issue>1</issue>
<fpage>45</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1097/WNR.0b013e32834e5af3</pub-id>
<pub-id pub-id-type="pmid">22107845</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yucel</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Coşkun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cengiz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ozdemir</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Uzar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Camkurt</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Aluclu</surname>
<given-names>MU</given-names>
</name>
</person-group>
<article-title>Association of polymorphisms within the serotonin receptor genes 5 - HTR1A, 5 - HTR1B, 5 - HTR2A and 5 - HTR2C and migraine susceptibility in a Turkish population</article-title>
<source/>Clin Psychopharmacol Neurosci
          <year>2016</year>
<volume>14</volume>
<issue>3</issue>
<fpage>250</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.9758/cpn.2016.14.3.250</pub-id>
<pub-id pub-id-type="pmid">27489378</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>GP</given-names>
</name>
</person-group>
<article-title>5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity</article-title>
<source/>Brain Res
          <year>2007</year>
<volume>1149</volume>
<fpage>14</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2007.02.038</pub-id>
<pub-id pub-id-type="pmid">17376412</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marcus</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Serotonin and its role in headache pathogenesis and treatment</article-title>
<source/>Clin J Pain
          <year>1993</year>
<volume>9</volume>
<issue>3</issue>
<fpage>159</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="doi">10.1097/00002508-199309000-00002</pub-id>
<pub-id pub-id-type="pmid">8219515</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huge</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kuhlenbaumer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kempt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seehafer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Evers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Marziniak</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genetic TPH2 variants and the susceptibility for migraine: association of a TPH2 haplotype with migraine without aura</article-title>
<source/>J neural transm
          <year>2010</year>
<volume>117</volume>
<issue>11</issue>
<fpage>1253</fpage>
<lpage>1260</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-010-0468-6</pub-id>
<pub-id pub-id-type="pmid">20740293</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Advances in tryptophan hydroxylase-2 gene expression regulation: new insights into serotonin-stress interaction and clinical implications</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2012</year>
<volume>159b</volume>
<issue>2</issue>
<fpage>152</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32023</pub-id>
<pub-id pub-id-type="pmid">22241550</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Tryptophan hydroxylase-2: an emerging therapeutic target for stress disorders</article-title>
<source/>Biochem Pharmacol
          <year>2013</year>
<volume>85</volume>
<issue>9</issue>
<fpage>1227</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2013.02.018</pub-id>
<pub-id pub-id-type="pmid">23435356</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Courtet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bellivier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Leboyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boulenger</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Castelhau</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lambercy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mouthon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Paoloni-Giacobino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vessaz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Malafosse</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Buresi</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Suicide attempts and the tryptophan hydroxylase gene</article-title>
<source/>Mol Psychiatry
          <year>2001</year>
<volume>6</volume>
<issue>3</issue>
<fpage>268</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4000846</pub-id>
<pub-id pub-id-type="pmid">11326294</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weng</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Burton</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Metabolomics approach reveals integrated metabolic network associated with serotonin deficiency</article-title>
<source/>Sci Rep
          <year>2015</year>
<volume>5</volume>
<fpage>11864</fpage>
<pub-id pub-id-type="doi">10.1038/srep11864</pub-id>
<pub-id pub-id-type="pmid">26154191</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutknecht</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Waider</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kraft</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kriegebaum</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Holtmann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Reif</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Deficiency of brain 5-HT synthesis but serotonergic neuron formation in Tph2 knockout mice</article-title>
<source/>J neural transm
          <year>2008</year>
<volume>115</volume>
<issue>8</issue>
<fpage>1127</fpage>
<lpage>1132</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-008-0096-6</pub-id>
<pub-id pub-id-type="pmid">18665319</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelosi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pratelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Migliarini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pacini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pasqualetti</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Generation of a Tph2 conditional knockout mouse line for time- and tissue-specific depletion of brain serotonin</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<issue>8</issue>
<fpage>e0136422</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0136422</pub-id>
<pub-id pub-id-type="pmid">26291320</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dussor</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Serotonin, 5HT1 agonists, and migraine: new data, but old questions still not answered</article-title>
<source/>Curr Opin Support Palliat Care
          <year>2014</year>
<volume>8</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1097/SPC.0000000000000044</pub-id>
<pub-id pub-id-type="pmid">24670810</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<mixed-citation publication-type="other">Ibrahimi K, Danser A, Terwindt G, van den Meiracker A, MaassenVanDenBrink A (2016) A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan. Cephalalgia. 0333102416637833</mixed-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>QP</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sirinathsinghji</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats</article-title>
<source/>Eur J Neurosci
          <year>2001</year>
<volume>13</volume>
<issue>11</issue>
<fpage>2099</fpage>
<lpage>2104</lpage>
<pub-id pub-id-type="doi">10.1046/j.0953-816x.2001.01586.x</pub-id>
<pub-id pub-id-type="pmid">11422450</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzoli</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan</article-title>
<source/>Neuropsychiatr dis treat
          <year>2014</year>
<volume>10</volume>
<fpage>547</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S25531</pub-id>
<pub-id pub-id-type="pmid">24729708</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harriott</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Scheff</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>The complex actions of sumatriptan on rat dural afferents</article-title>
<source/>Cephalalgia
          <year>2012</year>
<volume>32</volume>
<issue>10</issue>
<fpage>738</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="doi">10.1177/0333102412451356</pub-id>
<pub-id pub-id-type="pmid">22711897</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baillie</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Mulligan</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres</article-title>
<source/>Neuropharmacology
          <year>2012</year>
<volume>63</volume>
<issue>3</issue>
<fpage>362</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.04.016</pub-id>
<pub-id pub-id-type="pmid">22691374</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Jeffry</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Disney</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Premkumar</surname>
<given-names>LS</given-names>
</name>
</person-group>
<article-title>Sumatriptan inhibits TRPV1 channels in trigeminal neurons</article-title>
<source/>Headache
          <year>2012</year>
<volume>52</volume>
<issue>5</issue>
<fpage>773</fpage>
<lpage>784</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.2011.02053.x</pub-id>
<pub-id pub-id-type="pmid">22289052</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cameron</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>S-C</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kotb</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Skidmore</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Clifford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Triptans in the acute treatment of migraine: a systematic review and network meta-analysis</article-title>
<source/>Headache
          <year>2015</year>
<volume>55</volume>
<fpage>221</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1111/head.12601</pub-id>
<pub-id pub-id-type="pmid">26178694</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thorlund</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Druyts</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Goadsby</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis</article-title>
<source/>Cephalalgia
          <year>2014</year>
<volume>34</volume>
<issue>4</issue>
<fpage>258</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="doi">10.1177/0333102413508661</pub-id>
<pub-id pub-id-type="pmid">24108308</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hougaard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tfelt-Hansen</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Review of dose–response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists</article-title>
<source/>Expert Opin Drug Metab Toxicol
          <year>2015</year>
<volume>11</volume>
<issue>9</issue>
<fpage>1409</fpage>
<lpage>1418</lpage>
<pub-id pub-id-type="doi">10.1517/17425255.2015.1055244</pub-id>
<pub-id pub-id-type="pmid">26095133</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<mixed-citation publication-type="other">Christensen AF, Esserlind A-L, Werge T, Stefánsson H, Stefánsson K, Olesen J (2015) The influence of genetic constitution on migraine drug responses. Cephalalgia. 0333102415610874</mixed-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gentile</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chiossi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lionetto</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Martelletti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Borro</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic insights into migraine treatment in children</article-title>
<source/>Pharmacogenomics
          <year>2014</year>
<volume>15</volume>
<issue>11</issue>
<fpage>1539</fpage>
<lpage>1550</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.14.104</pub-id>
<pub-id pub-id-type="pmid">25303303</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buzzi</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Pathways to the best fit of triptans for migraine patients</article-title>
<source/>Cephalalgia
          <year>2008</year>
<volume>28</volume>
<issue>Suppl 2</issue>
<fpage>21</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-2982.2008.01687.x</pub-id>
<pub-id pub-id-type="pmid">18715329</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gentile</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Borro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Simmaco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Missori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lala</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Martelletti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy</article-title>
<source/>Expert Opin Drug Metab Toxicol
          <year>2011</year>
<volume>7</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1517/17425255.2011.538680</pub-id>
<pub-id pub-id-type="pmid">21142809</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terrazzino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Viana</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Floriddia</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mittino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sances</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tassorelli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nappi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rinaldi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Canonico</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Genazzani</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients</article-title>
<source/>Eur J Pharmacol
          <year>2010</year>
<volume>641</volume>
<issue>2–3</issue>
<fpage>82</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2010.04.049</pub-id>
<pub-id pub-id-type="pmid">20488209</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anttila</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Winsvold</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Gormley</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bettella</surname>
<given-names>F</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kallela</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Terwindt</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Medland</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Todt</surname>
<given-names>U</given-names>
</name>
<name>
<surname>McArdle</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Quaye</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Koiranen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ikram</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Lehtimaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stam</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Ligthart</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wedenoja</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dunham</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Palta</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hamalainen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schurks</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Buring</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stefansson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jakobsson</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lawlor</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Ring</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Farkkila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Artto</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kaunisto</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Freilinger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schoenen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Frants</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Pelzer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weller</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Zielman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Madden</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Borck</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gobel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Heinze</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heinze-Kuhn</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Hartikainen</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Pouta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van den Ende</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Uitterlinden</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Hofman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hottenga</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Vink</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Heikkila</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Muller-Myhsok</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meitinger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wichmann</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Aromaa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Traynor</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Trabzuni</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rossin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lage</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Birney</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kaprio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Penninx</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Boomsma</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>van Duijn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Raitakari</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Jarvelin</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Zwart</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cherkas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Strachan</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Kubisch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>van den Maagdenberg</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Dichgans</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wessman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Stefansson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Nyholt</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Chasman</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Palotie</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Genome-wide meta-analysis identifies new susceptibility loci for migraine</article-title>
<source/>Nat Genet
          <year>2013</year>
<volume>45</volume>
<issue>8</issue>
<fpage>912</fpage>
<lpage>917</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2676</pub-id>
<pub-id pub-id-type="pmid">23793025</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gentile</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Borro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lala</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Missori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Simmaco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martelletti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine</article-title>
<source/>J Headache Pain
          <year>2010</year>
<volume>11</volume>
<issue>5</issue>
<fpage>431</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="doi">10.1007/s10194-010-0241-0</pub-id>
<pub-id pub-id-type="pmid">20652353</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gentile</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Missori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Borro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sebastianelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Simmaco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martelletti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine</article-title>
<source/>J Headache Pain
          <year>2010</year>
<volume>11</volume>
<issue>2</issue>
<fpage>151</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1007/s10194-010-0202-7</pub-id>
<pub-id pub-id-type="pmid">20213484</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandl</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics of antipsychotics</article-title>
<source/>Can J Psychiatry
          <year>2014</year>
<volume>59</volume>
<issue>2</issue>
<fpage>76</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="pmid">24881126</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Everett</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>From metabonomics to pharmacometabonomics: the role of metabolic profiling in personalized medicine</article-title>
<source/>Front Pharmacol
          <year>2016</year>
<volume>7</volume>
<fpage>297</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2016.00297</pub-id>
<pub-id pub-id-type="pmid">27660611</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Biernacka</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hebbring</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Batzler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Drews</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Desta</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Flockhart</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mushiroda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kamatani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schaid</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weinshilboum</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Mrazek</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics</article-title>
<source/>Pharmacogenomics J
          <year>2013</year>
<volume>13</volume>
<issue>5</issue>
<fpage>456</fpage>
<lpage>463</lpage>
<pub-id pub-id-type="doi">10.1038/tpj.2012.32</pub-id>
<pub-id pub-id-type="pmid">22907730</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Neavin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Biernacka</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hall-Flavin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bobo</surname>
<given-names>WV</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Skime</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Batzler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kalari</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matson</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bhasin</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mushiroda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kaddurah-Daouk</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Weinshilboum</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics</article-title>
<source/>Mol Psychiatry
          <year>2016</year>
<volume>21</volume>
<issue>12</issue>
<fpage>1717</fpage>
<lpage>1725</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2016.6</pub-id>
<pub-id pub-id-type="pmid">26903268</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunn</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Sulis</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ferrando</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Greenwald</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>A conserved tetraspanin subfamily promotes Notch signaling in Caenorhabditis elegans and in human cells</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2010</year>
<volume>107</volume>
<issue>13</issue>
<fpage>5907</fpage>
<lpage>5912</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1001647107</pub-id>
<pub-id pub-id-type="pmid">20220101</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anthony</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lance</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Monoamine oxidase inhibition in the treatment of migraine</article-title>
<source/>Arch Neurol
          <year>1969</year>
<volume>21</volume>
<issue>3</issue>
<fpage>263</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.1969.00480150053007</pub-id>
<pub-id pub-id-type="pmid">5802458</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tfelt-Hansen</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Pihl</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hougaard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mitsikostas</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs</article-title>
<source/>Expert Opin Investig Drugs
          <year>2014</year>
<volume>23</volume>
<issue>3</issue>
<fpage>375</fpage>
<lpage>385</lpage>
<pub-id pub-id-type="doi">10.1517/13543784.2014.861817</pub-id>
<pub-id pub-id-type="pmid">24289494</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farkkila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Diener</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Geraud</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lainez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schoenen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Harner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pilgrim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reuter</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Efficacy and tolerability of lasmiditan, an oral 5-HT(1 F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study</article-title>
<source/>Lancet Neurol
          <year>2012</year>
<volume>11</volume>
<issue>5</issue>
<fpage>405</fpage>
<lpage>413</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70047-9</pub-id>
<pub-id pub-id-type="pmid">22459549</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viguier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Michot</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hamon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bourgoin</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Multiple roles of serotonin in pain control mechanisms —implications of 5-HT7 and other 5-HT receptor types</article-title>
<source/>Eur J Pharmacol
          <year>2013</year>
<volume>716</volume>
<issue>1–3</issue>
<fpage>8</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2013.01.074</pub-id>
<pub-id pub-id-type="pmid">23500207</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Miyoshi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dubner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Spinal 5-HT3 receptors mediate descending facilitation and contribute to behavioral hypersensitivity via a reciprocal neuron-glial signaling cascade</article-title>
<source/>Mol Pain
          <year>2014</year>
<volume>10</volume>
<fpage>35</fpage>
<pub-id pub-id-type="doi">10.1186/1744-8069-10-35</pub-id>
<pub-id pub-id-type="pmid">24913307</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haahr</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Frokjaer</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Mahon</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Baare</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Lehel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Norremolle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rabiner</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Knudsen</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study</article-title>
<source/>Mol Psychiatry
          <year>2014</year>
<volume>19</volume>
<issue>4</issue>
<fpage>427</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2013.147</pub-id>
<pub-id pub-id-type="pmid">24189342</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasefi</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kruk</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Heikkila</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Beazely</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons</article-title>
<source/>Mol Brain
          <year>2013</year>
<volume>6</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1186/1756-6606-6-24</pub-id>
<pub-id pub-id-type="pmid">23281934</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Ki</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JI</given-names>
</name>
</person-group>
<article-title>Expression of the spinal 5-HT7 receptor and p-ERK pathway in the carrageenan inflammatory pain of rats</article-title>
<source/>Korean J Anesthesiol
          <year>2015</year>
<volume>68</volume>
<issue>2</issue>
<fpage>170</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.4097/kjae.2015.68.2.170</pub-id>
<pub-id pub-id-type="pmid">25844136</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedlund</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>The 5-HT7 receptor and disorders of the nervous system: an overview</article-title>
<source/>Psychopharmacology (Berl)
          <year>2009</year>
<volume>206</volume>
<issue>3</issue>
<fpage>345</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-009-1626-0</pub-id>
<pub-id pub-id-type="pmid">19649616</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<mixed-citation publication-type="other">Jenkins TA, Nguyen JCD, Polglaze KE, Bertrand PP (2016) Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients 8(1). doi:10.3390/nu8010056</mixed-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Darlington</surname>
<given-names>LG</given-names>
</name>
</person-group>
<article-title>Endogenous kynurenines as targets for drug discovery and development</article-title>
<source/>Nat Rev Drug Discov
          <year>2002</year>
<volume>1</volume>
<issue>8</issue>
<fpage>609</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="doi">10.1038/nrd870</pub-id>
<pub-id pub-id-type="pmid">12402501</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richard</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Dawes</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Mathias</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Acheson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hill-Kapturczak</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dougherty</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications</article-title>
<source/>Int j tryptophan res
          <year>2009</year>
<volume>2</volume>
<fpage>45</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">20651948</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwarcz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Muchowski</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H-Q</given-names>
</name>
</person-group>
<article-title>Kynurenines in the mammalian brain: when physiology meets pathology</article-title>
<source/>Nat Rev Neurosci
          <year>2012</year>
<volume>13</volume>
<issue>7</issue>
<fpage>465</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3257</pub-id>
<pub-id pub-id-type="pmid">22678511</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujigaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences</article-title>
<source/>Neuropharmacology
          <year>2016</year>
<pub-id pub-id-type="pmid">26767951</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linderholm</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Skogh</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>M-L</given-names>
</name>
<name>
<surname>Holtze</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Engberg</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Samuelsson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Erhardt</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia</article-title>
<source/>Schizophr Bull
          <year>2012</year>
<volume>38</volume>
<issue>3</issue>
<fpage>426</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbq086</pub-id>
<pub-id pub-id-type="pmid">20729465</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lionetto</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Negro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Capi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perugino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fazio</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Giamberardino</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Simmaco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Martelletti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Altered serum levels of kynurenine metabolites in patients affected by cluster headache</article-title>
<source/>J Headache Pain
          <year>2015</year>
<volume>17</volume>
<issue>1</issue>
<fpage>27</fpage>
<pub-id pub-id-type="doi">10.1186/s10194-016-0620-2</pub-id>
<pub-id pub-id-type="pmid">27000870</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lionetto</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Negro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Capi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fazio</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Giamberardino</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Simmaco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Martelletti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Altered kynurenine pathway metabolites in serum of chronic migraine patients</article-title>
<source/>J Headache Pain
          <year>2015</year>
<volume>17</volume>
<fpage>47</fpage>
<pub-id pub-id-type="doi">10.1186/s10194-016-0638-5</pub-id>
<pub-id pub-id-type="pmid">27130315</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lionetto</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fazio</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mitsikostas</surname>
<given-names>D-D</given-names>
</name>
<name>
<surname>Martelletti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important</article-title>
<source/>Intern Emerg Med
          <year>2015</year>
<volume>10</volume>
<issue>4</issue>
<fpage>413</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="doi">10.1007/s11739-015-1208-6</pub-id>
<pub-id pub-id-type="pmid">25708356</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vecsei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Szalardy</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fulop</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Toldi</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Kynurenines in the CNS: recent advances and new questions</article-title>
<source/>Nat Rev Drug Discov
          <year>2013</year>
<volume>12</volume>
<issue>1</issue>
<fpage>64</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1038/nrd3793</pub-id>
<pub-id pub-id-type="pmid">23237916</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carpenter</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Pelton</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Gudin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kirwin</surname>
<given-names>PDS</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Heninger</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>McDougle</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Tryptophan depletion during continuous CSF sampling in healthy human subjects</article-title>
<source/>Neuropsychopharmacology
          <year>1998</year>
<volume>19</volume>
<issue>1</issue>
<fpage>26</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/S0893-133X(97)00198-X</pub-id>
<pub-id pub-id-type="pmid">9608574</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Shoaf</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Hommer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rawlings</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Linnoila</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers</article-title>
<source/>J Neurochem
          <year>1999</year>
<volume>72</volume>
<issue>4</issue>
<fpage>1641</fpage>
<lpage>1647</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.721641.x</pub-id>
<pub-id pub-id-type="pmid">10098872</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<mixed-citation publication-type="other">Sánchez CL, Van Swearingen AED, Arrant AE, Biskup CS, Kuhn CM, Zepf FD (2015) Simplified dietary acute tryptophan depletion: effects of a novel amino acid mixture on the neurochemistry of C57BL/6 J mice. 59. doi:10.3402/fnr.v59.27424</mixed-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biskup</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Arrant</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Van Swearingen</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zepf</surname>
<given-names>FD</given-names>
</name>
</person-group>
<article-title>Effects of acute tryptophan depletion on brain serotonin function and concentrations of dopamine and norepinephrine in C57BL/6 J and BALB/cJ mice</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<issue>5</issue>
<fpage>e35916</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0035916</pub-id>
<pub-id pub-id-type="pmid">22629305</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Van Swearingen</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Arrant</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Zepf</surname>
<given-names>FD</given-names>
</name>
</person-group>
<article-title>Dietary manipulation of serotonergic and dopaminergic function in C57BL/6 J mice with amino acid depletion mixtures</article-title>
<source/>J neural transm
          <year>2014</year>
<volume>121</volume>
<issue>2</issue>
<fpage>153</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-013-1083-0</pub-id>
<pub-id pub-id-type="pmid">24061481</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eccleston</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ashcroft</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>TB</given-names>
</name>
</person-group>
<article-title>Effect of tryptophan administration on 5HIAA in cerebrospinal fluid in man</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1970</year>
<volume>33</volume>
<issue>2</issue>
<fpage>269</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.33.2.269</pub-id>
<pub-id pub-id-type="pmid">5443486</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>SN</given-names>
</name>
</person-group>
<article-title>Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects</article-title>
<source/>J Psychiat Neurosci
          <year>2013</year>
<volume>38</volume>
<issue>5</issue>
<fpage>294</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="doi">10.1503/jpn.120209</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>SN</given-names>
</name>
</person-group>
<article-title>How to increase serotonin in the human brain without drugs</article-title>
<source/>J Psychiat Neurosci
          <year>2007</year>
<volume>32</volume>
<issue>6</issue>
<fpage>394</fpage>
<lpage>399</lpage>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>TSS</given-names>
</name>
<name>
<surname>Asha</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Ramesh</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>KSJ</given-names>
</name>
</person-group>
<article-title>Understanding nutrition, depression and mental illnesses</article-title>
<source/>Indian J Psychiatry
          <year>2008</year>
<volume>50</volume>
<issue>2</issue>
<fpage>77</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.4103/0019-5545.42391</pub-id>
<pub-id pub-id-type="pmid">19742217</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wurtman</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Dietary treatments that affect brain neurotransmitters</article-title>
<source/>Ann N Y Acad Sci
          <year>1987</year>
<volume>499</volume>
<issue>1</issue>
<fpage>179</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1987.tb36209.x</pub-id>
<pub-id pub-id-type="pmid">2886101</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drummond</surname>
<given-names>PD</given-names>
</name>
</person-group>
<article-title>Tryptophan depletion increases nausea, headache and photophobia in migraine sufferers</article-title>
<source/>Cephalalgia
          <year>2006</year>
<volume>26</volume>
<issue>10</issue>
<fpage>1225</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-2982.2006.01212.x</pub-id>
<pub-id pub-id-type="pmid">16961791</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kangasniemi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Falck</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Langvik</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Hyyppa</surname>
<given-names>MT</given-names>
</name>
</person-group>
<article-title>Levotryptophan treatment in migraine</article-title>
<source/>Headache
          <year>1978</year>
<volume>18</volume>
<issue>3</issue>
<fpage>161</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1978.hed1803161.x</pub-id>
<pub-id pub-id-type="pmid">352998</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steardo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sorge</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Florio</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>L-tryptophan treatment in essential headache: preliminary data</article-title>
<source/>Acta Neurol (Napoli)
          <year>1977</year>
<volume>32</volume>
<issue>5</issue>
<fpage>613</fpage>
<lpage>623</lpage>
<pub-id pub-id-type="pmid">337762</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shabbir</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mattison</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krishnamohan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sandhu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nel</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rais</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sandhu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ngu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Effect of diet on serotonergic neurotransmission in depression</article-title>
<source/>Neurochem Int
          <year>2013</year>
<volume>62</volume>
<issue>3</issue>
<fpage>324</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2012.12.014</pub-id>
<pub-id pub-id-type="pmid">23306210</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gyermek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Pharmacology of serotonin as related to anesthesia</article-title>
<source/>J Clin Anesth
          <year>1996</year>
<volume>8</volume>
<issue>5</issue>
<fpage>402</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1016/0952-8180(96)00093-1</pub-id>
<pub-id pub-id-type="pmid">8832453</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Claustrat</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Loisy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beorchia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Arnaud</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Chazot</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Nocturnal plasma melatonin levels in migraine - a preliminary-report</article-title>
<source/>Headache
          <year>1989</year>
<volume>29</volume>
<issue>4</issue>
<fpage>242</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1989.hed22904242.x</pub-id>
<pub-id pub-id-type="pmid">2714976</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murialdo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fonzi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Costelli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Solinas</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Parodi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Marabini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fanciullacci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Polleri</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine</article-title>
<source/>Cephalalgia
          <year>1994</year>
<volume>14</volume>
<issue>3</issue>
<fpage>205</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1994.014003205.x</pub-id>
<pub-id pub-id-type="pmid">7954740</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Claustrat</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Saddier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chazot</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses</article-title>
<source/>Cephalalgia
          <year>1995</year>
<volume>15</volume>
<issue>2</issue>
<fpage>136</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1995.015002136.x</pub-id>
<pub-id pub-id-type="pmid">7641249</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruera</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sances</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Leston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cristina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Medina</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Barontini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nappi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Figuerola</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Plasma melatonin pattern in chronic and episodic headaches: evaluation during sleep and waking</article-title>
<source/>Funct Neurol
          <year>2008</year>
<volume>23</volume>
<issue>2</issue>
<fpage>77</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">18671907</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peres</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Sanchez del Rio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seabra</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Tufik</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Abucham</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cipolla-Neto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Silberstein</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Zukerman</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Hypothalamic involvement in chronic migraine</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2001</year>
<volume>71</volume>
<issue>6</issue>
<fpage>747</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.71.6.747</pub-id>
<pub-id pub-id-type="pmid">11723194</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masruha</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>de Souza Vieira</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Minett</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Cipolla-Neto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zukerman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vilanova</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Peres</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Low urinary 6-sulphatoxymelatonin concentrations in acute migraine</article-title>
<source/>J Headache Pain
          <year>2008</year>
<volume>9</volume>
<issue>4</issue>
<fpage>221</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1007/s10194-008-0047-5</pub-id>
<pub-id pub-id-type="pmid">18594760</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masruha</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Souza Vieira</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Minett</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Cipolla-Neto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zukerman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vilanova</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Peres</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities</article-title>
<source/>Headache
          <year>2010</year>
<volume>50</volume>
<issue>3</issue>
<fpage>413</fpage>
<lpage>419</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.2009.01547.x</pub-id>
<pub-id pub-id-type="pmid">19817880</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jadhav</surname>
<given-names>HR</given-names>
</name>
</person-group>
<article-title>Melatonin: functions and ligands</article-title>
<source/>Drug Discov Today
          <year>2014</year>
<volume>19</volume>
<issue>9</issue>
<fpage>1410</fpage>
<lpage>1418</lpage>
<pub-id pub-id-type="doi">10.1016/j.drudis.2014.04.014</pub-id>
<pub-id pub-id-type="pmid">24792719</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badawy</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide</article-title>
<source/>Psychopharmacology (Berl)
          <year>2013</year>
<volume>228</volume>
<issue>3</issue>
<fpage>347</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3191-9</pub-id>
<pub-id pub-id-type="pmid">23828158</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>WZ</given-names>
</name>
<name>
<surname>Gwee</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Moochhalla</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>KY</given-names>
</name>
</person-group>
<article-title>Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study</article-title>
<source/>Aliment Pharmacol Ther
          <year>2005</year>
<volume>22</volume>
<issue>10</issue>
<fpage>927</fpage>
<lpage>934</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2036.2005.02673.x</pub-id>
<pub-id pub-id-type="pmid">16268966</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Zanette</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Vercelino</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Laste</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rozisky</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Schwertner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Xavier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>de Souza</surname>
<given-names>ICC</given-names>
</name>
<name>
<surname>Deitos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>ILS</given-names>
</name>
<name>
<surname>Caumo</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial</article-title>
<source/>BMC Pharmacol Toxicol
          <year>2014</year>
<volume>15</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1186/2050-6511-15-40</pub-id>
<pub-id pub-id-type="pmid">24417770</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andersen</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Gogenur</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Reiter</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>The safety of melatonin in humans</article-title>
<source/>Clin Drug Investig
          <year>2016</year>
<volume>36</volume>
<issue>3</issue>
<fpage>169</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1007/s40261-015-0368-5</pub-id>
<pub-id pub-id-type="pmid">26692007</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peres</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Masruha</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Zukerman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Moreira-Filho</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Cavalheiro</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Potential therapeutic use of melatonin in migraine and other headache disorders</article-title>
<source/>Expert Opin Investig Drugs
          <year>2006</year>
<volume>15</volume>
<issue>4</issue>
<fpage>367</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="doi">10.1517/13543784.15.4.367</pub-id>
<pub-id pub-id-type="pmid">16548786</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bougea</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spantideas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lyras</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Avramidis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Thomaidis</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Melatonin 4 mg as prophylactic therapy for primary headaches: a pilot study</article-title>
<source/>Funct Neurol
          <year>2016</year>
<volume>31</volume>
<issue>1</issue>
<fpage>33</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">27027892</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Members: IHSCTS</collab>
<name>
<surname>Tfelt-Hansen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pascual</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ramadan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dahlöf</surname>
<given-names>C</given-names>
</name>
<name>
<surname>D’Amico</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Diener</surname>
<given-names>H-C</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lanteri-Minet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Loder</surname>
<given-names>E</given-names>
</name>
<name>
<surname>McCrory</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Plancade</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schwedt</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators</article-title>
<source/>Cephalalgia
          <year>2012</year>
<volume>32</volume>
<issue>1</issue>
<fpage>6</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1177/0333102411417901</pub-id>
<pub-id pub-id-type="pmid">22384463</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peres</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Zukerman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>da Cunha</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Cipolla-Neto</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Melatonin, 3 mg, is effective for migraine prevention</article-title>
<source/>Neurology
          <year>2004</year>
<volume>63</volume>
<issue>4</issue>
<fpage>757</fpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000134653.35587.24</pub-id>
<pub-id pub-id-type="pmid">15326268</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Parisi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pelliccia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Luchetti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paolino</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Melatonin to prevent migraine or tension-type headache in children</article-title>
<source/>Neurol Sci
          <year>2008</year>
<volume>29</volume>
<issue>4</issue>
<fpage>285</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1007/s10072-008-0983-5</pub-id>
<pub-id pub-id-type="pmid">18810607</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alstadhaug</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Odeh</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Salvesen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bekkelund</surname>
<given-names>SI</given-names>
</name>
</person-group>
<article-title>Prophylaxis of migraine with melatonin: a randomized controlled trial</article-title>
<source/>Neurology
          <year>2010</year>
<volume>75</volume>
<issue>17</issue>
<fpage>1527</fpage>
<lpage>1532</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f9618c</pub-id>
<pub-id pub-id-type="pmid">20975054</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fallah</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shoroki</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Ferdosian</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Safety and efficacy of melatonin in pediatric migraine prophylaxis</article-title>
<source/>Curr Drug Saf
          <year>2015</year>
<volume>10</volume>
<issue>2</issue>
<fpage>132</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.2174/1574886309666140605114614</pub-id>
<pub-id pub-id-type="pmid">24909684</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Tryptamine: a neuromodulator or neurotransmitter in mammalian brain?</article-title>
<source/>Prog Neurobiol
          <year>1982</year>
<volume>19</volume>
<issue>1–2</issue>
<fpage>117</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/0301-0082(82)90023-5</pub-id>
<pub-id pub-id-type="pmid">6131482</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mousseau</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders</article-title>
<source/>Metab Brain Dis
          <year>1993</year>
<volume>8</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1007/BF01000528</pub-id>
<pub-id pub-id-type="pmid">8098507</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>D’Amico</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bussone</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bolner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aguggia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saracco</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Galloni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>De Riva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>D’Arrigo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Colavito</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Leon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perini</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Tryptamine levels are low in plasma of chronic migraine and chronic tension-type headache</article-title>
<source/>Neurol Sci
          <year>2014</year>
<volume>35</volume>
<issue>12</issue>
<fpage>1941</fpage>
<lpage>1945</lpage>
<pub-id pub-id-type="doi">10.1007/s10072-014-1867-5</pub-id>
<pub-id pub-id-type="pmid">25016960</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cevoli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Colavito</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Leon</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Biochemistry of primary headaches: role of tyrosine and tryptophan metabolism</article-title>
<source/>Neurol Sci
          <year>2015</year>
<volume>36</volume>
<issue>1</issue>
<fpage>17</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1007/s10072-015-2131-3</pub-id>
<pub-id pub-id-type="pmid">26017505</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>D’Amico</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bussone</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bolner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aguggia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saracco</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Galloni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>De Riva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Colavito</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Leon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rosteghin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Perini</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>The role of tyrosine metabolism in the pathogenesis of chronic migraine</article-title>
<source/>Cephalalgia
          <year>2013</year>
<volume>33</volume>
<issue>11</issue>
<fpage>932</fpage>
<lpage>937</lpage>
<pub-id pub-id-type="doi">10.1177/0333102413480755</pub-id>
<pub-id pub-id-type="pmid">23493762</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<mixed-citation publication-type="other">D’Andrea G, Leone M, Bussone G, Fiore PD, Bolner A, Aguggia M, Saracco MG, Perini F, Giordano G, Gucciardi A, Leon A (2016) Abnormal tyrosine metabolism in chronic cluster headache. Cephalalgia. doi:10.1177/0333102416640502</mixed-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stahl</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders</article-title>
<source/>Arch Gen Psychiatry
          <year>1977</year>
<volume>34</volume>
<issue>5</issue>
<fpage>509</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1977.01770170019001</pub-id>
<pub-id pub-id-type="pmid">140632</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerring</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rodriguez-Acevedo</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Nyholt</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>Blood gene expression studies in migraine: potential and caveats</article-title>
<source/>Cephalalgia
          <year>2016</year>
<volume>36</volume>
<issue>7</issue>
<fpage>669</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="doi">10.1177/0333102416628463</pub-id>
<pub-id pub-id-type="pmid">26862113</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saulin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Savli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lanzenberger</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Serotonin and molecular neuroimaging in humans using PET</article-title>
<source/>Amino Acids
          <year>2012</year>
<volume>42</volume>
<issue>6</issue>
<fpage>2039</fpage>
<lpage>2057</lpage>
<pub-id pub-id-type="doi">10.1007/s00726-011-1078-9</pub-id>
<pub-id pub-id-type="pmid">21947614</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paterson</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Kornum</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Nutt</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Pike</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Knudsen</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>5-HT radioligands for human brain imaging with PET and SPECT</article-title>
<source/>Med Res Rev
          <year>2013</year>
<volume>33</volume>
<issue>1</issue>
<fpage>54</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1002/med.20245</pub-id>
<pub-id pub-id-type="pmid">21674551</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<mixed-citation publication-type="other">Fumita M, Robert BI In vivo molecular imaging: ligand development and research applications. In: in Neuropsychopharmacology: The Fifth Generation of Progress, 2000. Citeseer,</mixed-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willeit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Praschak-Rieder</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: a review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry</article-title>
<source/>Neuroimage
          <year>2010</year>
<volume>53</volume>
<issue>3</issue>
<fpage>878</fpage>
<lpage>892</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.04.030</pub-id>
<pub-id pub-id-type="pmid">20399868</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishizawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leyton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okazawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Benkelfat</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mzengeza</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Diksic</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Validation of a less-invasive method for measurement of serotonin synthesis rate with alpha-[11C]methyl-tryptophan</article-title>
<source/>J Cereb Blood Flow Metab
          <year>1998</year>
<volume>18</volume>
<issue>10</issue>
<fpage>1121</fpage>
<lpage>1129</lpage>
<pub-id pub-id-type="doi">10.1097/00004647-199810000-00009</pub-id>
<pub-id pub-id-type="pmid">9778189</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muzik</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Chugani</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mangner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chugani</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>Analysis of [C-11]alpha-methyl-tryptophan kinetics for the estimation of serotonin synthesis rate in vivo</article-title>
<source/>J Cereb Blood Flow Metab
          <year>1997</year>
<volume>17</volume>
<issue>6</issue>
<fpage>659</fpage>
<lpage>669</lpage>
<pub-id pub-id-type="doi">10.1097/00004647-199706000-00007</pub-id>
<pub-id pub-id-type="pmid">9236722</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chugani</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Niimura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chaturvedi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muzik</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Fakhouri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Chugani</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>Increased brain serotonin synthesis in migraine</article-title>
<source/>Neurology
          <year>1999</year>
<volume>53</volume>
<issue>7</issue>
<fpage>1473</fpage>
<lpage>1479</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.53.7.1473</pub-id>
<pub-id pub-id-type="pmid">10534254</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lothe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Merlet</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Demarquay</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Costes</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ryvlin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mauguiere</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Interictal brain 5-HT1A receptors binding in migraine without aura: a 18 F-MPPF-PET study</article-title>
<source/>Cephalalgia
          <year>2008</year>
<volume>28</volume>
<issue>12</issue>
<fpage>1282</fpage>
<lpage>1291</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-2982.2008.01677.x</pub-id>
<pub-id pub-id-type="pmid">18727636</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuh-Hofer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Geworski</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Villringer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Israel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wenzel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Munz</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Increased serotonin transporter availability in the brainstem of migraineurs</article-title>
<source/>J Neurol
          <year>2007</year>
<volume>254</volume>
<issue>6</issue>
<fpage>789</fpage>
<lpage>796</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-006-0444-0</pub-id>
<pub-id pub-id-type="pmid">17351723</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dobson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Diksic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aube</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis</article-title>
<source/>Neurology
          <year>2008</year>
<volume>70</volume>
<issue>6</issue>
<fpage>431</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000299095.65331.6f</pub-id>
<pub-id pub-id-type="pmid">18250288</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobson</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Tohyama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Diksic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain</article-title>
<source/>Cephalalgia
          <year>2004</year>
<volume>24</volume>
<issue>1</issue>
<fpage>2</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-2982.2004.00647.x</pub-id>
<pub-id pub-id-type="pmid">14687006</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Diksic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aube</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>alpha-[11C] methyl-L tryptophan-PET as a surrogate for interictal cerebral serotonin synthesis in migraine without aura</article-title>
<source/>Cephalalgia
          <year>2014</year>
<volume>34</volume>
<issue>3</issue>
<fpage>165</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1177/0333102413506126</pub-id>
<pub-id pub-id-type="pmid">24057438</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>KY</given-names>
</name>
</person-group>
<article-title>Increased brainstem serotonergic transporter availability in adult migraineurs: an [(18)F]FP-CIT PET imaging pilot study</article-title>
<source/>Nucl med mol imaging
          <year>2016</year>
<volume>50</volume>
<issue>1</issue>
<fpage>70</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1007/s13139-015-0373-x</pub-id>
<pub-id pub-id-type="pmid">26941862</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrington</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid biomarkers in primary headache disorders</article-title>
<source/>Headache
          <year>2006</year>
<volume>46</volume>
<issue>7</issue>
<fpage>1075</fpage>
<lpage>1087</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.2006.00501.x</pub-id>
<pub-id pub-id-type="pmid">16866712</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jowett</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A pharmacological investigation of cerebro-spinal fluid from patients with migraine</article-title>
<source/>Brain
          <year>1967</year>
<volume>90</volume>
<issue>4</issue>
<fpage>785</fpage>
<lpage>794</lpage>
<pub-id pub-id-type="doi">10.1093/brain/90.4.785</pub-id>
<pub-id pub-id-type="pmid">6075811</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kangasni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sonninen</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rinne</surname>
<given-names>UK</given-names>
</name>
</person-group>
<article-title>Excretion of free and conjugated 5-HIAA and VMA in urine and concentration of 5-HIAA and HVA in CSF during migraine attacks and free intervals</article-title>
<source/>Headache
          <year>1972</year>
<volume>12</volume>
<issue>2</issue>
<fpage>62</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1972.hed1202062.x</pub-id>
<pub-id pub-id-type="pmid">5056180</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Eich</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>IJ</given-names>
</name>
</person-group>
<article-title>A possible role for saliva as a diagnostic fluid in patients with chronic pain</article-title>
<source/>Semin Arthritis Rheum
          <year>1998</year>
<volume>27</volume>
<issue>6</issue>
<fpage>348</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1016/S0049-0172(98)80014-0</pub-id>
<pub-id pub-id-type="pmid">9662753</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolodi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Del Bianco</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polypeptide in human saliva: their pattern in migraine and cluster headache</article-title>
<source/>Cephalalgia
          <year>1990</year>
<volume>10</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1990.1001039.x</pub-id>
<pub-id pub-id-type="pmid">1690601</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Holsinger</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Bui</surname>
<given-names>D</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Myers</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ferris</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Anatomy, function, and evaluation of the salivary glands</article-title>
<source/>Salivary gland disorders
          <year>2007</year>
<publisher-loc>Berlin</publisher-loc>
<publisher-name>Springer</publisher-name>
<fpage>1</fpage>
<lpage>16</lpage>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cady</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Vause</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Bigal</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Durham</surname>
<given-names>PL</given-names>
</name>
</person-group>
<article-title>Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan</article-title>
<source/>Headache
          <year>2009</year>
<volume>49</volume>
<issue>9</issue>
<fpage>1258</fpage>
<lpage>1266</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.2009.01523.x</pub-id>
<pub-id pub-id-type="pmid">19788468</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellamy</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Cady</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Durham</surname>
<given-names>PL</given-names>
</name>
</person-group>
<article-title>Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients</article-title>
<source/>Headache
          <year>2006</year>
<volume>46</volume>
<issue>1</issue>
<fpage>24</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.2006.00294.x</pub-id>
<pub-id pub-id-type="pmid">16412148</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marukawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shimomura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Salivary substance P, 5-hydroxytryptamine, and gamma-aminobutyric acid levels in migraine and tension-type headache</article-title>
<source/>Headache
          <year>1996</year>
<volume>36</volume>
<issue>2</issue>
<fpage>100</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.1046/j.1526-4610.1996.3602101.x</pub-id>
<pub-id pub-id-type="pmid">8742682</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tajti</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Szok</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Majlath</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Tuka</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Csati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vecsei</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Migraine and neuropeptides</article-title>
<source/>Neuropeptides
          <year>2015</year>
<volume>52</volume>
<fpage>19</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.npep.2015.03.006</pub-id>
<pub-id pub-id-type="pmid">26094101</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iantorno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Campia</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Di Daniele</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nistico</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Forleo</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Cardillo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tesauro</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Obesity, inflammation and endothelial dysfunction</article-title>
<source/>J Biol Regul Homeost Agents
          <year>2014</year>
<volume>28</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="pmid">25001649</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murinova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Krashin</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Vascular risk in migraineurs: interaction of endothelial and cortical excitability factors</article-title>
<source/>Headache
          <year>2014</year>
<volume>54</volume>
<issue>3</issue>
<fpage>583</fpage>
<lpage>590</lpage>
<pub-id pub-id-type="doi">10.1111/head.12304</pub-id>
<pub-id pub-id-type="pmid">24512140</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller Alyson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Budzyn</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sobey Christopher</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Vascular dysfunction in cerebrovascular disease: mechanisms and therapeutic intervention</article-title>
<source/>Clin Sci
          <year>2010</year>
<volume>119</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1042/CS20090649</pub-id>
<pub-id pub-id-type="pmid">20370718</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<mixed-citation publication-type="other">Lenart N, Brough D, Denes A (2016) Inflammasomes link vascular disease with neuroinflammation and brain disorders. J Cereb Blood Flow Metab. doi:10.1177/0271678x16662043</mixed-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernatova</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Endothelial dysfunction in experimental models of arterial hypertension: cause or consequence?</article-title>
<source/>Biomed Res Int
          <year>2014</year>
<volume>2014</volume>
<fpage>14</fpage>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalkara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nozari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moskowitz</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Migraine aura pathophysiology: the role of blood vessels and microembolisation</article-title>
<source/>Lancet Neurol
          <year>2010</year>
<volume>9</volume>
<issue>3</issue>
<fpage>309</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(09)70358-8</pub-id>
<pub-id pub-id-type="pmid">20170844</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurth</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Migraine a marker of vascular health?</article-title>
<source/>Cephalalgia
          <year>2013</year>
<volume>33</volume>
<issue>4</issue>
<fpage>226</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1177/0333102412472074</pub-id>
<pub-id pub-id-type="pmid">23291286</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pierangeli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Giannini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Favoni</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sambati</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cevoli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cortelli</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Migraine and cardiovascular diseases</article-title>
<source/>Neurol Sci
          <year>2012</year>
<volume>33</volume>
<issue>Suppl 1</issue>
<fpage>S47</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1007/s10072-012-1040-y</pub-id>
<pub-id pub-id-type="pmid">22644170</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jernej</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Vladic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cicin-Sain</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hranilovic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Banovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Balija</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bilic</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sucic</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Vukadin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Grgicevic</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Platelet serotonin measures in migraine</article-title>
<source/>Headache
          <year>2002</year>
<volume>42</volume>
<issue>7</issue>
<fpage>588</fpage>
<lpage>595</lpage>
<pub-id pub-id-type="doi">10.1046/j.1526-4610.2002.02145.x</pub-id>
<pub-id pub-id-type="pmid">12482210</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gill</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Pant</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Saksena</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Singla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nazir</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Vohwinkel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alrefai</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Dudeja</surname>
<given-names>PK</given-names>
</name>
</person-group>
<article-title>Function, expression, and characterization of the serotonin transporter in the native human intestine</article-title>
<source/>Am J Physiol Gastrointest Liver Physiol
          <year>2008</year>
<volume>294</volume>
<issue>1</issue>
<fpage>G254</fpage>
<lpage>G262</lpage>
<pub-id pub-id-type="doi">10.1152/ajpgi.00354.2007</pub-id>
<pub-id pub-id-type="pmid">17991706</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<mixed-citation publication-type="other">Van Hemert S, Breedveld A, Rovers J, Vermeiden J, Witteman B, Smits M, de Roos N (2014) Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Frontiers in Neurology 5. doi:10.3389/fneur.2014.00241</mixed-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mawe</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Serotonin signaling in the gastrointestinal tract: functions, dysfunctions, and therapeutic targets</article-title>
<source/>Nat Rev Gastroenterol Hepatol
          <year>2013</year>
<volume>10</volume>
<issue>8</issue>
<fpage>473</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1038/nrgastro.2013.105</pub-id>
<pub-id pub-id-type="pmid">23797870</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Wolozin</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Reiderer</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter</article-title>
<source/>J Neurochem
          <year>1993</year>
<volume>60</volume>
<issue>6</issue>
<fpage>2319</fpage>
<lpage>2322</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.1993.tb03522.x</pub-id>
<pub-id pub-id-type="pmid">7684072</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose’Meyer</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>A review of the serotonin transporter and prenatal cortisol in the development of autism spectrum disorders</article-title>
<source/>Molecular Autism
          <year>2013</year>
<volume>4</volume>
<fpage>37</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-4-37</pub-id>
<pub-id pub-id-type="pmid">24103554</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bengel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Wichems</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Feltner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Heils</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mossner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Westphal</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice</article-title>
<source/>Mol Pharmacol
          <year>1998</year>
<volume>53</volume>
<issue>4</issue>
<fpage>649</fpage>
<lpage>655</lpage>
<pub-id pub-id-type="pmid">9547354</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Tolliver</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Wichems</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter</article-title>
<source/>Neuropharmacology
          <year>2005</year>
<volume>49</volume>
<issue>6</issue>
<fpage>798</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2005.08.010</pub-id>
<pub-id pub-id-type="pmid">16183083</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altamura</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dell’Acqua</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Moessner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Altered neocortical cell density and layer thickness in serotonin transporter knockout mice: a quantitation study</article-title>
<source/>Cereb Cortex
          <year>2007</year>
<volume>17</volume>
<issue>6</issue>
<fpage>1394</fpage>
<lpage>1401</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhl051</pub-id>
<pub-id pub-id-type="pmid">16905592</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nietzer</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Bonn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Heiming</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Lewejohann</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sachser</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Asan</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Serotonin transporter knockout and repeated social defeat stress: Impact on neuronal morphology and plasticity in limbic brain areas</article-title>
<source/>Behav Brain Res
          <year>2011</year>
<volume>220</volume>
<issue>1</issue>
<fpage>42</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2011.01.011</pub-id>
<pub-id pub-id-type="pmid">21238500</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanington</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Migraine - the platelet hypothesis after 10 years</article-title>
<source/>Biomed Pharmacother
          <year>1989</year>
<volume>43</volume>
<issue>10</issue>
<fpage>719</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1016/0753-3322(89)90160-1</pub-id>
<pub-id pub-id-type="pmid">2701286</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danese</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Montagnana</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lippi</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Platelets and migraine</article-title>
<source/>Thromb Res
          <year>2014</year>
<volume>134</volume>
<issue>1</issue>
<fpage>17</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/j.thromres.2014.03.055</pub-id>
<pub-id pub-id-type="pmid">24767953</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horvath</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Selby</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Poskitt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hyland</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Coulter-Mackie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stockler-Ipsiroglu</surname>
<given-names>SG</given-names>
</name>
</person-group>
<article-title>Hemiplegic migraine, seizures, progressive spastic paraparesis, mood disorder, and coma in siblings with low systemic serotonin</article-title>
<source/>Cephalalgia
          <year>2011</year>
<volume>31</volume>
<issue>15</issue>
<fpage>1580</fpage>
<lpage>1586</lpage>
<pub-id pub-id-type="doi">10.1177/0333102411420584</pub-id>
<pub-id pub-id-type="pmid">22013141</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hasselmark</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Alecci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cananzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Platelet secretion from dense and alpha-granules in vitro in migraine with or without aura</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1994</year>
<volume>57</volume>
<issue>5</issue>
<fpage>557</fpage>
<lpage>561</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.57.5.557</pub-id>
<pub-id pub-id-type="pmid">8201323</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovacs</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Filep</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jelencsik</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Magyar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Csanda</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Platelet aggregation of migraineurs during and between attacks</article-title>
<source/>Cephalalgia
          <year>1990</year>
<volume>10</volume>
<issue>4</issue>
<fpage>161</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1990.1004161.x</pub-id>
<pub-id pub-id-type="pmid">2245463</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goubau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Buyse</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Van Geet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Freson</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The contribution of platelet studies to the understanding of disease mechanisms in complex and monogenetic neurological disorders</article-title>
<source/>Dev Med Child Neurol
          <year>2014</year>
<volume>56</volume>
<issue>8</issue>
<fpage>724</fpage>
<lpage>731</lpage>
<pub-id pub-id-type="doi">10.1111/dmcn.12421</pub-id>
<pub-id pub-id-type="pmid">24579816</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tietjen</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Khubchandani</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Platelet dysfunction and stroke in the female migraineur</article-title>
<source/>Curr Pain Headache Rep
          <year>2009</year>
<volume>13</volume>
<issue>5</issue>
<fpage>386</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="doi">10.1007/s11916-009-0063-4</pub-id>
<pub-id pub-id-type="pmid">19728966</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franco</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schettino</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Filho</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Vendramin</surname>
<given-names>FS</given-names>
</name>
</person-group>
<article-title>Protocol for obtaining platelet-rich plasma (PRP), platelet-poor plasma (PPP), and thrombin for autologous use</article-title>
<source/>Aesthetic Plast Surg
          <year>2012</year>
<volume>36</volume>
<issue>5</issue>
<fpage>1254</fpage>
<lpage>1259</lpage>
<pub-id pub-id-type="doi">10.1007/s00266-012-9957-3</pub-id>
<pub-id pub-id-type="pmid">22936376</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brand</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis</article-title>
<source/>Clin Chem
          <year>2011</year>
<volume>57</volume>
<issue>10</issue>
<fpage>1376</fpage>
<lpage>1386</lpage>
<pub-id pub-id-type="doi">10.1373/clinchem.2011.163824</pub-id>
<pub-id pub-id-type="pmid">21859903</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dvilansky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rishpon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nathan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Zolotow</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Korczyn</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Release of Platelet 5-Hydroxytryptamine by Plasma Taken from Patients during and between Migraine Attacks</article-title>
<source/>Pain
          <year>1976</year>
<volume>2</volume>
<issue>3</issue>
<fpage>315</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1016/0304-3959(76)90009-9</pub-id>
<pub-id pub-id-type="pmid">1026904</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrari</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Odink</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tapparelli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Van Kempen</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Pennings</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Bruyn</surname>
<given-names>GW</given-names>
</name>
</person-group>
<article-title>Serotonin metabolism in migraine</article-title>
<source/>Neurology
          <year>1989</year>
<volume>39</volume>
<issue>9</issue>
<fpage>1239</fpage>
<lpage>1242</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.39.9.1239</pub-id>
<pub-id pub-id-type="pmid">2475821</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milovanovic</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Majkic-Sing</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mirkovic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pavlovic</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Plasma and urinary serotonin and 5-hydroxyindol-3-acetic acid in adults with migraine and tension-type headache</article-title>
<source/>Adv Exp Med Biol
          <year>1999</year>
<volume>467</volume>
<fpage>191</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-4615-4709-9_25</pub-id>
<pub-id pub-id-type="pmid">10721056</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curran</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Hinterberger</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lance</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects</article-title>
<source/>Brain
          <year>1965</year>
<volume>88</volume>
<issue>5</issue>
<fpage>997</fpage>
<lpage>1010</lpage>
<pub-id pub-id-type="doi">10.1093/brain/88.5.997</pub-id>
<pub-id pub-id-type="pmid">5325360</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rydzewski</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Serotonin (5HT) in migraine: levels in whole blood in and between attacks</article-title>
<source/>Headache
          <year>1976</year>
<volume>16</volume>
<issue>1</issue>
<fpage>16</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1976.hed1601016.x</pub-id>
<pub-id pub-id-type="pmid">1254466</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagata</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hamada</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gotoh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Plasma 5-hydroxytryptamine (5-HT) in migraine during an attack-free period</article-title>
<source/>Headache
          <year>2006</year>
<volume>46</volume>
<issue>4</issue>
<fpage>592</fpage>
<lpage>596</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.2006.00408.x</pub-id>
<pub-id pub-id-type="pmid">16643553</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deanovic</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Iskric</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dupelj</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Fluctuation of 5-hydroxy-indole compounds in urine of migrainous patients</article-title>
<source/>Biomed Express
          <year>1975</year>
<volume>23</volume>
<issue>9</issue>
<fpage>346</fpage>
<lpage>349</lpage>
</element-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bousser</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Elghozi</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Laude</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Soisson</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Urinary 5-HIAA in migraine - evidence of lowered excretion in young adult females</article-title>
<source/>Cephalalgia
          <year>1986</year>
<volume>6</volume>
<issue>4</issue>
<fpage>205</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1986.0604205.x</pub-id>
<pub-id pub-id-type="pmid">2433045</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curzon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Theaker</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Excretion of 5-hydroxyindolyl acetic acid (5HIAA) in migraine</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1966</year>
<volume>29</volume>
<issue>1</issue>
<fpage>85</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.29.1.85</pub-id>
<pub-id pub-id-type="pmid">5910583</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Headache</collab>
</person-group>
<article-title>Ad Hoc committe on classification of headache</article-title>
<source/>JAMA
          <year>1962</year>
<volume>179</volume>
<fpage>717</fpage>
<pub-id pub-id-type="doi">10.1001/jama.1962.03050090045008</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<label>194.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>Headache</collab>
</person-group>
<source/>World federation of neurology research group on migraine and headache. Definition of migraine. Background to migraine
          <year>1970</year>
<publisher-loc>London</publisher-loc>
<publisher-name>Heineman</publisher-name>
</element-citation>
</ref>
<ref id="CR195">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>IHS</collab>
</person-group>
<article-title>Classification and diagnostic criteria for the headache disorders, cranial neuralgias and facial pain</article-title>
<source/>Cephalalgia
          <year>1988</year>
<volume>8</volume>
<fpage>1</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1988.0801001.x</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peterlin</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Clinical pharmacology of the serotonin receptor agonist, zolmitriptan</article-title>
<source/>Expert Opin Drug Metab Toxicol
          <year>2007</year>
<volume>3</volume>
<issue>6</issue>
<fpage>899</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="doi">10.1517/17425255.3.6.899</pub-id>
<pub-id pub-id-type="pmid">18028032</pub-id>
</element-citation>
</ref>
<ref id="CR197">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crook</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Migraine: a biochemical headache?</article-title>
<source/>Biochem Soc Trans
          <year>1981</year>
<volume>9</volume>
<issue>4</issue>
<fpage>351</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="doi">10.1042/bst0090351</pub-id>
<pub-id pub-id-type="pmid">7021259</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anthony</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lance</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Plasma serotonin in patients with chronic tension headaches</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1989</year>
<volume>52</volume>
<issue>2</issue>
<fpage>182</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.52.2.182</pub-id>
<pub-id pub-id-type="pmid">2703837</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Risch</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Nemeroff</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Neurochemical alterations of serotonergic neuronal systems in depression</article-title>
<source/>J Clin Psychiatry
          <year>1992</year>
<volume>53</volume>
<issue>Suppl</issue>
<fpage>3</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">1331029</pub-id>
</element-citation>
</ref>
<ref id="CR200">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mawe</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Coates</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Moses</surname>
<given-names>PL</given-names>
</name>
</person-group>
<article-title>Review article: intestinal serotonin signalling in irritable bowel syndrome</article-title>
<source/>Aliment Pharmacol Ther
          <year>2006</year>
<volume>23</volume>
<issue>8</issue>
<fpage>1067</fpage>
<lpage>1076</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02858.x</pub-id>
<pub-id pub-id-type="pmid">16611266</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Shimeall</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sessums</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dezee</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Becher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Diemer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berbano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>O’Malley</surname>
<given-names>PG</given-names>
</name>
</person-group>
<article-title>Tricyclic antidepressants and headaches: systematic review and meta-analysis</article-title>
<source/>BMJ
          <year>2010</year>
<volume>341</volume>
<fpage>c5222</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.c5222</pub-id>
<pub-id pub-id-type="pmid">20961988</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Supornsilpchai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sanguanrangsirikul</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maneesri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Srikiatkhachorn</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Serotonin depletion, cortical spreading depression, and trigeminal nociception</article-title>
<source/>Headache
          <year>2006</year>
<volume>46</volume>
<issue>1</issue>
<fpage>34</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.2006.00310.x</pub-id>
<pub-id pub-id-type="pmid">16412149</pub-id>
</element-citation>
</ref>
<ref id="CR203">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maneesri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Supornsilpchai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Saengjaroentham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pleumsamran</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Srikiatkhachorn</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Effect of serotonin depletion on cortical spreading depression evoked cerebrovascular changes</article-title>
<source/>Asian Biomed
          <year>2010</year>
<volume>4</volume>
<issue>5</issue>
<fpage>731</fpage>
<lpage>738</lpage>
</element-citation>
</ref>
<ref id="CR204">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>le Grand</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Supornsilpchai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Saengjaroentham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Srikiatkhachorn</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Serotonin depletion leads to cortical hyperexcitability and trigeminal nociceptive facilitation via the nitric oxide pathway</article-title>
<source/>Headache
          <year>2011</year>
<volume>51</volume>
<issue>7</issue>
<fpage>1152</fpage>
<lpage>1160</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.2011.01931.x</pub-id>
<pub-id pub-id-type="pmid">21649655</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<label>205.</label>
<mixed-citation publication-type="other">Dumas M-E, Davidovic L (2013) Metabolic phenotyping and systems biology approaches to understanding neurological disorders. F1000Prime Reports 5:18. doi:10.12703/P5-18</mixed-citation>
</ref>
<ref id="CR206">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wishart</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Tzur</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Knox</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Eisner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jewell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Arndt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sawhney</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nikolai</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Coutouly</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Forsythe</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Shrivastava</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jeroncic</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stothard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Amegbey</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Block</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hau</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Miniaci</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Clements</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gebremedhin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Duggan</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Macinnis</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Weljie</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Dowlatabadi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bamforth</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Clive</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Greiner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marrie</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sykes</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Querengesser</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>HMDB: the human metabolome database</article-title>
<source/>Nucleic Acids Res
          <year>2007</year>
<volume>35</volume>
<issue>Database issue</issue>
<fpage>D521</fpage>
<lpage>526</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkl923</pub-id>
<pub-id pub-id-type="pmid">17202168</pub-id>
</element-citation>
</ref>
<ref id="CR207">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shyti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kohler</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Schoenmaker</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Derks</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Tolner</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Mayboroda</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>van den Maagdenberg</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Plasma metabolic profiling after cortical spreading depression in a transgenic mouse model of hemiplegic migraine by capillary electrophoresis--mass spectrometry</article-title>
<source/>Mol Biosyst
          <year>2015</year>
<volume>11</volume>
<issue>5</issue>
<fpage>1462</fpage>
<lpage>1471</lpage>
<pub-id pub-id-type="doi">10.1039/C5MB00049A</pub-id>
<pub-id pub-id-type="pmid">25856790</pub-id>
</element-citation>
</ref>
<ref id="CR208">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouatra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aziat</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Knox</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bjorndahl</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Krishnamurthy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Saleem</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dame</surname>
<given-names>ZT</given-names>
</name>
<name>
<surname>Poelzer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huynh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yallou</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Psychogios</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bogumil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Roehring</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wishart</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>The human urine metabolome</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<issue>9</issue>
<fpage>e73076</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0073076</pub-id>
<pub-id pub-id-type="pmid">24023812</pub-id>
</element-citation>
</ref>
<ref id="CR209">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Psychogios</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hau</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bouatra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sinelnikov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Krishnamurthy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Eisner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gautam</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Knox</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hollander</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Bamforth</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Greiner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McManus</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Goodfriend</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wishart</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>The human serum metabolome</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<issue>2</issue>
<fpage>e16957</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0016957</pub-id>
<pub-id pub-id-type="pmid">21359215</pub-id>
</element-citation>
</ref>
<ref id="CR210">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalsgaard-Nielsen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Genefke</surname>
<given-names>IK</given-names>
</name>
</person-group>
<article-title>Serotonin (5-Hydroxytryptamine) release and uptake in platelets from healthy persons and migrainous patients in attack-free intervals</article-title>
<source/>Headache: J Head Face Pain
          <year>1974</year>
<volume>14</volume>
<issue>1</issue>
<fpage>26</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1974.hed1401026.x</pub-id>
</element-citation>
</ref>
<ref id="CR211">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalendovsky</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Complicated migraine its association with increased platelet aggregability and abnormal plasma coagulation-factors</article-title>
<source/>Headache
          <year>1975</year>
<volume>15</volume>
<issue>1</issue>
<fpage>18</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1975.hed1501018.x</pub-id>
<pub-id pub-id-type="pmid">1132988</pub-id>
</element-citation>
</ref>
<ref id="CR212">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muck-Seler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Deanovic</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dupelj</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Platelet serotonin (5-HT) and 5-HT releasing factor in plasma of migrainous patients</article-title>
<source/>Headache
          <year>1979</year>
<volume>19</volume>
<issue>1</issue>
<fpage>14</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1979.hed1901014.x</pub-id>
<pub-id pub-id-type="pmid">759400</pub-id>
</element-citation>
</ref>
<ref id="CR213">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rolf</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Wiele</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brune</surname>
<given-names>GG</given-names>
</name>
</person-group>
<article-title>5-Hydroxytryptamine in platelets of patients with muscle contraction headache</article-title>
<source/>Headache
          <year>1981</year>
<volume>21</volume>
<issue>1</issue>
<fpage>10</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1981.hed2101010.x</pub-id>
<pub-id pub-id-type="pmid">7461964</pub-id>
</element-citation>
</ref>
<ref id="CR214">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Coppen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Swade</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Blood platelet 5-hydroxytryptamine accumulation and migraine</article-title>
<source/>Adv Neurol
          <year>1982</year>
<volume>33</volume>
<fpage>233</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="pmid">7055002</pub-id>
</element-citation>
</ref>
<ref id="CR215">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oxman</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Hitzemann</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Platelet membrane lipid composition and the frequency of migraine</article-title>
<source/>Headache
          <year>1982</year>
<volume>22</volume>
<issue>6</issue>
<fpage>261</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1982.hed2206261.x</pub-id>
<pub-id pub-id-type="pmid">7174303</pub-id>
</element-citation>
</ref>
<ref id="CR216">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Launay</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Pradalier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dreux</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dry</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Platelet serotonin uptake and migraine</article-title>
<source/>Cephalalgia
          <year>1982</year>
<volume>2</volume>
<issue>2</issue>
<fpage>57</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1982.0202057.x</pub-id>
<pub-id pub-id-type="pmid">7127456</pub-id>
</element-citation>
</ref>
<ref id="CR217">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pradalier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Launay</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Dry</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dreux</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Role of platelet serotonin in common migraine - concentrations and uptake</article-title>
<source/>Presse Med
          <year>1983</year>
<volume>12</volume>
<issue>37</issue>
<fpage>2311</fpage>
<lpage>2314</lpage>
<pub-id pub-id-type="pmid">6226980</pub-id>
</element-citation>
</ref>
<ref id="CR218">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kruglak</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nathan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Korczyn</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Zolotov</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Berginer</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dvilansky</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Platelet aggregability, disaggregability and serotonin uptake in migraine</article-title>
<source/>Cephalalgia
          <year>1984</year>
<volume>4</volume>
<issue>4</issue>
<fpage>221</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1984.0404221.x</pub-id>
<pub-id pub-id-type="pmid">6518502</pub-id>
</element-citation>
</ref>
<ref id="CR219">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lechner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ott</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fazekas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pilger</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Evidence of enhanced platelet aggregation and platelet sensitivity in migraine patients</article-title>
<source/>Cephalalgia
          <year>1985</year>
<volume>5</volume>
<issue>Suppl 2</issue>
<fpage>89</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">3160475</pub-id>
</element-citation>
</ref>
<ref id="CR220">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lingjaerde</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Monstad</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The uptake, storage, and efflux of serotonin in platelets from migraine patients</article-title>
<source/>Cephalalgia
          <year>1986</year>
<volume>6</volume>
<issue>3</issue>
<fpage>135</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1986.0603135.x</pub-id>
<pub-id pub-id-type="pmid">3768947</pub-id>
</element-citation>
</ref>
<ref id="CR221">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shukla</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shanker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nag</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bhargava</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Serotonin in tension headache</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1987</year>
<volume>50</volume>
<issue>12</issue>
<fpage>1682</fpage>
<lpage>1684</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.50.12.1682</pub-id>
<pub-id pub-id-type="pmid">3437303</pub-id>
</element-citation>
</ref>
<ref id="CR222">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kozubski</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Walkowiak</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cierniewski</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Prusinski</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Platelet fibrinogen receptors in migraine patients</article-title>
<source/>Headache
          <year>1987</year>
<volume>27</volume>
<issue>8</issue>
<fpage>431</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1987.hed2708431.x</pub-id>
<pub-id pub-id-type="pmid">3667260</pub-id>
</element-citation>
</ref>
<ref id="CR223">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joseph</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Grunfeld</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Oster</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Cytosolic ionized calcium homeostasis in platelets: an abnormal sensitivity to PAF-activation in migraine</article-title>
<source/>Headache
          <year>1988</year>
<volume>28</volume>
<issue>6</issue>
<fpage>396</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1988.hed2806396.x</pub-id>
<pub-id pub-id-type="pmid">2844693</pub-id>
</element-citation>
</ref>
<ref id="CR224">
<label>224.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Grunfeld</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nagel-Leiby</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Platelet norepinephrine and serotonin balance in migraine</article-title>
<source/>Headache
          <year>1989</year>
<volume>29</volume>
<issue>10</issue>
<fpage>657</fpage>
<lpage>659</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1989.hed2910657.x</pub-id>
<pub-id pub-id-type="pmid">2613514</pub-id>
</element-citation>
</ref>
<ref id="CR225">
<label>225.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Riddle</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Grunfeld</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Platelet serotonin metabolism and ultrastructure in migraine</article-title>
<source/>Arch Neurol
          <year>1989</year>
<volume>46</volume>
<issue>11</issue>
<fpage>1187</fpage>
<lpage>1189</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.1989.00520470041024</pub-id>
<pub-id pub-id-type="pmid">2479367</pub-id>
</element-citation>
</ref>
<ref id="CR226">
<label>226.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herman</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Magyar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Filep</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Decreased sensitivity of platelets to platelet-activating factor in migraine patients during the headache-free interval</article-title>
<source/>Thromb Haemost
          <year>1989</year>
<volume>62</volume>
<issue>2</issue>
<fpage>818</fpage>
<pub-id pub-id-type="pmid">2814933</pub-id>
</element-citation>
</ref>
<ref id="CR227">
<label>227.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeshima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Urakami</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Muscle contraction headache and migraine. Platelet activation and plasma norepinephrine during the cold pressor test</article-title>
<source/>Cephalalgia
          <year>1989</year>
<volume>9</volume>
<issue>1</issue>
<fpage>7</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1989.901007.x</pub-id>
<pub-id pub-id-type="pmid">2706677</pub-id>
</element-citation>
</ref>
<ref id="CR228">
<label>228.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riddle</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McElroy</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Grunfeld</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Christopherson</surname>
<given-names>TG</given-names>
</name>
</person-group>
<article-title>Platelet activation and analysis of organelles in migraineurs</article-title>
<source/>Headache
          <year>1989</year>
<volume>29</volume>
<issue>1</issue>
<fpage>28</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1989.hed2901028.x</pub-id>
<pub-id pub-id-type="pmid">2925372</pub-id>
</element-citation>
</ref>
<ref id="CR229">
<label>229.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Govitrapong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Limthavon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Srikiatkhachorn</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>5-HT2 serotonin receptor on blood platelet of migraine patients</article-title>
<source/>Headache
          <year>1992</year>
<volume>32</volume>
<issue>10</issue>
<fpage>480</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1992.hed3210480.x</pub-id>
<pub-id pub-id-type="pmid">1468904</pub-id>
</element-citation>
</ref>
<ref id="CR230">
<label>230.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotrim</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>CAF</given-names>
</name>
<name>
<surname>Demacedo</surname>
<given-names>TDA</given-names>
</name>
</person-group>
<article-title>Changes in platelet membrane fluidity of migraine patients</article-title>
<source/>Cephalalgia
          <year>1993</year>
<volume>13</volume>
<issue>2</issue>
<fpage>99</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1993.1302099.x</pub-id>
<pub-id pub-id-type="pmid">8495463</pub-id>
</element-citation>
</ref>
<ref id="CR231">
<label>231.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jensen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hindberg</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Plasma serotonin increase during episodes of tension-type headache</article-title>
<source/>Cephalalgia
          <year>1994</year>
<volume>14</volume>
<issue>3</issue>
<fpage>219</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1994.014003219.x</pub-id>
<pub-id pub-id-type="pmid">7954743</pub-id>
</element-citation>
</ref>
<ref id="CR232">
<label>232.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shimomura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takeshima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Increased 11-dehydrothromboxane B2 in migraine: platelet hyperfunction in patients with migraine during headache-free period</article-title>
<source/>Headache
          <year>1994</year>
<volume>34</volume>
<issue>9</issue>
<fpage>515</fpage>
<lpage>518</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1994.hed3409515.x</pub-id>
<pub-id pub-id-type="pmid">8002323</pub-id>
</element-citation>
</ref>
<ref id="CR233">
<label>233.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jarman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pattichis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Peatfield</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Glover</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sandler</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Red wine-induced release of [14C]5-hydroxytryptamine from platelets of migraine patients and controls</article-title>
<source/>Cephalalgia
          <year>1996</year>
<volume>16</volume>
<issue>1</issue>
<fpage>41</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1996.1601041.x</pub-id>
<pub-id pub-id-type="pmid">8825698</pub-id>
</element-citation>
</ref>
<ref id="CR234">
<label>234.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fioroni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Andrea</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Alecci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cananzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Facchinetti</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Platelet serotonin pathway in menstrual migraine</article-title>
<source/>Cephalalgia
          <year>1996</year>
<volume>16</volume>
<issue>6</issue>
<fpage>427</fpage>
<lpage>430</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1996.1606427.x</pub-id>
<pub-id pub-id-type="pmid">8902252</pub-id>
</element-citation>
</ref>
<ref id="CR235">
<label>235.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srikiatkhachorn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anthony</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Platelet serotonin in patients with analgesic-induced headache</article-title>
<source/>Cephalalgia
          <year>1996</year>
<volume>16</volume>
<issue>6</issue>
<fpage>423</fpage>
<lpage>426</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1996.1606423.x</pub-id>
<pub-id pub-id-type="pmid">8902251</pub-id>
</element-citation>
</ref>
<ref id="CR236">
<label>236.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pukhal’skaya</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Kolosova</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Men’shikov</surname>
<given-names>MY</given-names>
</name>
</person-group>
<article-title>Serotonin-induced platelet aggregation and release of3H-serotonin in patients with migraine</article-title>
<source/>Bull Exp Biol Med
          <year>1998</year>
<volume>126</volume>
<issue>2</issue>
<fpage>780</fpage>
<lpage>782</lpage>
<pub-id pub-id-type="doi">10.1007/BF02446908</pub-id>
</element-citation>
</ref>
<ref id="CR237">
<label>237.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oishi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mochizuki</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>beta-thromboglobulin and 11-dehydrothromboxane B-2 in tension-type headache</article-title>
<source/>Headache
          <year>1998</year>
<volume>38</volume>
<issue>9</issue>
<fpage>676</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="doi">10.1046/j.1526-4610.1998.3809676.x</pub-id>
<pub-id pub-id-type="pmid">15613179</pub-id>
</element-citation>
</ref>
<ref id="CR238">
<label>238.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srikiatkhachorn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maneesri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Govitrapong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kasantikul</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Derangement of serotonin system in migrainous patients with analgesic abuse headache: clues from platelets</article-title>
<source/>Headache
          <year>1998</year>
<volume>38</volume>
<issue>1</issue>
<fpage>43</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1046/j.1526-4610.1998.3801043.x</pub-id>
<pub-id pub-id-type="pmid">9505003</pub-id>
</element-citation>
</ref>
<ref id="CR239">
<label>239.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarchielli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Alberti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Baldi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gallai</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Floridi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Floridi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Capocchi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gallai</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks</article-title>
<source/>Cephalalgia
          <year>2004</year>
<volume>24</volume>
<issue>8</issue>
<fpage>623</fpage>
<lpage>630</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-2982.2003.00717.x</pub-id>
<pub-id pub-id-type="pmid">15265050</pub-id>
</element-citation>
</ref>
<ref id="CR240">
<label>240.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yucel</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tanriverdi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arikanoglu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Varol</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Akil</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Celepkolu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Uzar</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Increased fibrinogen, D-dimer and galectin-3 levels in patients with migraine</article-title>
<source/>Neurol Sci
          <year>2014</year>
<volume>35</volume>
<issue>4</issue>
<fpage>545</fpage>
<lpage>549</lpage>
<pub-id pub-id-type="doi">10.1007/s10072-013-1542-2</pub-id>
<pub-id pub-id-type="pmid">24057117</pub-id>
</element-citation>
</ref>
<ref id="CR241">
<label>241.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couch</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Hassanein</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Platelet aggregability in migraine and relation of aggregability to clinical aspects of migraine</article-title>
<source/>Neurology
          <year>1976</year>
<volume>26</volume>
<issue>4</issue>
<fpage>348</fpage>
<lpage>348</lpage>
</element-citation>
</ref>
<ref id="CR242">
<label>242.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couch</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Hassanein</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Platelet aggregability in migraine</article-title>
<source/>Neurology
          <year>1977</year>
<volume>27</volume>
<issue>9</issue>
<fpage>843</fpage>
<lpage>848</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.27.9.843</pub-id>
<pub-id pub-id-type="pmid">561334</pub-id>
</element-citation>
</ref>
<ref id="CR243">
<label>243.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deshmukh</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Cyclic changes in platelet dynamics and the pathogenesis and prophylaxis of migraine</article-title>
<source/>Headache
          <year>1977</year>
<volume>17</volume>
<issue>3</issue>
<fpage>101</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1977.hed1703101.x</pub-id>
<pub-id pub-id-type="pmid">893079</pub-id>
</element-citation>
</ref>
<ref id="CR244">
<label>244.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Manzoni</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Moretti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Poti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tagliaferri</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Study of platelet function in patients with migraine</article-title>
<source/>Haematologica
          <year>1983</year>
<volume>68</volume>
<issue>6</issue>
<fpage>775</fpage>
<lpage>781</lpage>
<pub-id pub-id-type="pmid">6230297</pub-id>
</element-citation>
</ref>
<ref id="CR245">
<label>245.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waldenlind</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Saaf</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ekbom</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wetterberg</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Concentration and uptake of 5-hydroxytryptamine in platelets from cluster headache and migraine patients</article-title>
<source/>Cephalalgia
          <year>1985</year>
<volume>5</volume>
<issue>1</issue>
<fpage>45</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1985.0501045.x</pub-id>
<pub-id pub-id-type="pmid">3921257</pub-id>
</element-citation>
</ref>
<ref id="CR246">
<label>246.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buttinelli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lazzaro</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Lenzi</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Paolucci</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Prencipe</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Correlation between migraine and circulating platelet aggregates</article-title>
<source/>Cephalalgia
          <year>1985</year>
<volume>5</volume>
<issue>Suppl 2</issue>
<fpage>87</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="pmid">4016945</pub-id>
</element-citation>
</ref>
<ref id="CR247">
<label>247.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walkowiak</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kozubski</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pawlowska</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Prusinski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cierniewski</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Expression of fibrinogen receptors in platelets of migraine patients--correlation with platelet GPIIb content and plasma cholesterol</article-title>
<source/>Thromb Haemost
          <year>1989</year>
<volume>61</volume>
<issue>3</issue>
<fpage>419</fpage>
<lpage>422</lpage>
<pub-id pub-id-type="pmid">2799757</pub-id>
</element-citation>
</ref>
<ref id="CR248">
<label>248.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joseph</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Serotonergic hypofunction in migraine: a synthesis of evidence based on platelet dense body dysfunction</article-title>
<source/>Cephalalgia
          <year>1989</year>
<volume>9</volume>
<issue>4</issue>
<fpage>293</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1989.904293.x</pub-id>
<pub-id pub-id-type="pmid">2611888</pub-id>
</element-citation>
</ref>
<ref id="CR249">
<label>249.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribeiro</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Cotrim</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Morgadinho</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>de Macedo</surname>
<given-names>TR</given-names>
</name>
</person-group>
<article-title>Migraine, serum serotonin and platelet 5-HT2 receptors</article-title>
<source/>Cephalalgia
          <year>1990</year>
<volume>10</volume>
<issue>5</issue>
<fpage>213</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1990.1005213.x</pub-id>
<pub-id pub-id-type="pmid">2272090</pub-id>
</element-citation>
</ref>
<ref id="CR250">
<label>250.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Varma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kar</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Platelet aggregation in migraine</article-title>
<source/>J Assoc Physicians India
          <year>1992</year>
<volume>40</volume>
<issue>3</issue>
<fpage>153</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="pmid">1634476</pub-id>
</element-citation>
</ref>
<ref id="CR251">
<label>251.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leira</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Prieto</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Noya</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Platelet-rich plasma serotonin levels in tension-type headache and depression</article-title>
<source/>Cephalalgia
          <year>1993</year>
<volume>13</volume>
<issue>5</issue>
<fpage>346</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1046/j.1468-2982.1993.1305346.x</pub-id>
<pub-id pub-id-type="pmid">8242728</pub-id>
</element-citation>
</ref>
<ref id="CR252">
<label>252.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Andrea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hasselmark</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cananzi</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Alecci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zamberlan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Metabolism and menstrual cycle rhythmicity of serotonin in primary headaches</article-title>
<source/>Headache
          <year>1995</year>
<volume>35</volume>
<issue>4</issue>
<fpage>216</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1111/j.1526-4610.1995.hed3504216.x</pub-id>
<pub-id pub-id-type="pmid">7539781</pub-id>
</element-citation>
</ref>
<ref id="CR253">
<label>253.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allais</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Facco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ciochetto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>De Lorenzo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fiore</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Benedetto</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Patterns of platelet aggregation in menstrual migraine</article-title>
<source/>Cephalalgia
          <year>1997</year>
<volume>17</volume>
<issue>Suppl 20</issue>
<fpage>39</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">9496778</pub-id>
</element-citation>
</ref>
<ref id="CR254">
<label>254.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeller</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lindner</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Frahm</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Baron</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Deuschl</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Platelet activation and platelet-leucocyte interaction in patients with migraine. Subtype differences and influence of triptans</article-title>
<source/>Cephalalgia
          <year>2005</year>
<volume>25</volume>
<issue>7</issue>
<fpage>536</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-2982.2005.00916.x</pub-id>
<pub-id pub-id-type="pmid">15955041</pub-id>
</element-citation>
</ref>
<ref id="CR255">
<label>255.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taffi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vignini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lanciotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Luconi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nanetti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mazzanti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Provinciali</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Silvestrini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bartolini</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Platelet membrane fluidity and peroxynitrite levels in migraine patients during headache-free periods</article-title>
<source/>Cephalalgia
          <year>2005</year>
<volume>25</volume>
<issue>5</issue>
<fpage>353</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-2982.2004.00863.x</pub-id>
<pub-id pub-id-type="pmid">15839850</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>